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ABSTRACT 
We previously demonstrated a regulatory role for intracellular Ca2+ ([Ca2+]i) in 
human and murine adipocyte metabolism, with increased [Ca2+]i coordinately stimulating 
lipogenesis and inhibiting lipolysis, thereby expanding adipocyte lipid mass. More 
recently, we reported that la, 25-dihydroxyvitamin D3 [la, 25-(0H)i-D3] stimulates 
adipocyte membrane vitamin D receptor (m VDR)-mediated Ca2+ influx, resulting in a 
similar Ca2+-mediated modulation of adipocyte lipid metabolism. la, 25-(0H)i-D3 also 
exerts an inhibitory effect on adipocyte uncoupling protein 2 (UCP2) mRNA and protein 
levels via the nuclear vitamin D receptor (n VDR), independent of its effects on Ca2+ 
influx. Furthermore, we reported that suppressing la, 25-(0H)i-D3 levels by increasing 
dietary calcium reduces adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis, 
increases thermo genesis, and consequently results in attenuation of adipocyte lipid 
accretion and weight/fat gain during over-consumption and acceleration of weight/fat loss 
during energy restriction. Notably, dairy sources of calcium exerted significantly greater 
effects than calcium in the form of calcium carbonate, although the reason for this is not 
yet clear. This thesis study was conducted to extend these observations by determining 
the efficacy of a fermented dairy product, yogurt, presented either unflavored or 
strawberry-flavored, compared to calcium carbonate, in accelerating weight/fat loss 
secondary to caloric restriction in aP2-agouti transgenic mice. Mice were fed a low 
calcium (0.4%)/high fat/high sucrose diet for 6 weeks in order to induce obesity. Mice 
were then either maintained on the same low calcium basal diet ad lib or energy-
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restricted (70% of ad lib) on this diet either unsupplemented (basal) or supplemented 
with calcium content increased to 1.2% either by replacing 34% of the protein with spray 
dried plain or strawberry-flavored yogurt (with macronutrient adjustments) or by adding 
calcium carbonate for 6 weeks. Adipocyte [Ca2+]i was only slightly decreased by energy 
restriction alone but was further markedly reduced by all three high calcium diets (170±6 
nM, n=lO vs. 60±5 nM, n=30, p<0.001). The three high calcium diets caused significant 
stimulation of both basal and isoproterenol-stimulated lipolysis (78%-137%, p<0.05), 
with yogurt exerting a significantly greater effect compared to calcium carbonate 
(p<0.05). Similarly, the three high calcium diets suppressed adipocyte FAS mRNA by an 
average of 87%. Body weight, as well as individual and total fat pad weights, reflected 
these changes, with a 45% augmentation in fat loss on the two yogurt diets compared to 
that on the low calcium diet secondary to caloric restriction (p<0.001). Calcium carbonate 
supplementation produced an intermediate effect, with a lower 28% augmentation in fat 
loss compared to that on the low calcium diet secondary to caloric restriction. 
Furthermore, high calcium diets caused a higher core temperature and an increased white 
adipose tissue UCP2 expression, indicating increased thermogenesis and decreased 
metabolic efficiency. In conclusion, our data show that dietary calcium with calcium 
sources from plain yogurt, strawberry-flavored yogurt and calcium carbonate supplement 
suppress adipocyte [Ca2+]i and up-regulate UCP2 via suppression of la, 25-(0H)2-D3, and 
thereby reduce energy storage, decrease metabolic efficiency and accelerate weight/ fat 
loss during energy restriction, with significantly greater effects exerted by yogurt than by 
V 
supplemental calcium. Consistent with the animal observations, accumulating human 
studies strongly support an anti-obesity role for dietary calcium. Therefore, dietary 
calcium, especially dairy calcium, may be effective dietary regimen for the treatment of 
obesity. 
Vl 
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Obesity has reached epidemic proportions in the United States and is threatening to 
become a global epidemic (1). Overeating and physical inactivity in combination with 
genetic factors play the most important roles in the development of obesity (2). Since 
obesity is strongly associated with an increased incidence of chronic diseases (3), weight 
loss itself has been proven to be beneficial to reduce the morbidity and mortality risk 
associated with obesity (4-6). Americans spend about $40 billion per year on weight-loss 
treatments, mostly in the form of diets and dietary foods. And this approach seems to be 
ineffective (7). 
Since McCarron first noted a significant inverse relationship between dietary calcium 
intake and body weight in his NHANES I data analysis in 1984 (8), accumulating body of 
evidence strongly support the anti-obesity role of dietary calcium (9-22). However, it is 
not until recently that the mechanism underlying this dietary calcium modulation of 
adiposity is explored. 
Previous studies of the mechanism of action of the agouti gene in obesity and insulin 
resistance from our laboratory demonstrated a regulatory role for intracellular Ca2+ 
concentration ([Ca2+]i) in human and murine adipocyte lipid metabolism (23-26). 
Increased adipocyte [Ca2+]i appears to promote expansion of adipocyte triglyceride stores 
by exerting a coordinated stimulation of lipogenesis and inhibition of lipolysis. 
Moreover, obesity in transgenic mice ubiquitously expressing agouti under the control of 
the P-actin promoter was markedly attenuated by 4-week treatment of a Ca2+ - channel 
antagonist (nifedipine) (27). 
2 
More recently, we reported that la,25-(0H)2-D3 stimulates adipocyte Ca2+ influx via 
the m VDR, resulting in a similar Ca2+ -mediated modulation of adipocyte lipid 
metabolism (13, 28). la, 25-(0H)2-D3 also exerts an inhibitory effect on adipocyte UCP2 
mRNA and protein levels via the n VDR, independent of its effects on Ca2+ influx (29). 
Furthermore, we reported that feeding high calcium diets (non-fat dry milk) results in 
decreased adipocyte [Ca2ii, increased thermogenesis, and attenuation of adipocyte lipid 
accretion and weight/fat gain in ad libitum fed mice and marked acceleration of 
weight/fat loss secondary to caloric restriction (13, 16, 17). Accordingly, we proposed 
that suppressing la,25-(0H)2-D3 levels by increasing dietary calcium would suppress 
adipocyte [Ca21i, up-regulate UCP2, and consequently inhibit lipogenesis, stimulate 
lipolysis, increase thermogenesis and decrease metabolic efficiency, thereby exerting an 
anti-obesity effect. 
Consistent with the animal observations, clinical and epidemiological observations 
support these findings (13, 15, 21). Epidemiologically, the effect of calcium intake on fat 
mass in humans was examined in the NHANES III data set (13). After controlling for 
energy intake and energy expenditure, a strong inverse relationship was noted between 
calcium intake and body fat in both women and men. The odds ratio of being in the 
highest quartile of body fat was markedly reduced from 1.00 for the first quartile of 
calcium intake to 0.75, 0.40, and 0.16 for the second, third, and fourth quartiles of 
calcium intake, respectively. 
Collectively, dietary calcium may exert its anti-obesity effect for humans through the 
mechanism we proposed above, and further investigation is needed to confirm this. 
Notably, dairy sources of calcium exerted substantially greater effects in acceleration of 
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weight/loss secondary to caloric restriction compared to the same levels of calcium in the 
form of calcium carbonate supplement (13, 16, 17) although the additional component(s) 
of dairy products responsible for this difference is not yet known. Moreover, the only 
dairy product systematically tested in this manner has been non-fat dry milk (13, 16), and 
it is not clear whether other forms of dairy products will exert comparable or greater 
weight-loss effects secondary to caloric restriction. Accordingly, the objective of this 
thesis research is to determine the efficacy of a fermented dairy product, yogurt, 
presented either unflavored or strawberry-flavored, compared to calcium carbonate, in 
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I. Obesity Epidemic 
Obesity is a chronic disease involving genetic predisposition, environmental 
influences and behavioral aspects and results in significant morbidity, reduced quality of 
life, discrimination and early mortality (1 ). Obesity is objectively assessed by body mass 
index (BMI), which is defined as weight of an individual in kg divided by height squared 
in meters (kg/m2). Based on the facts that with increased degree of overweight and 
obesity there is an increase in morbidity and mortality risk (2-4), the World Health 
Organization (WHO) and the International Obesity Task Force (IOTF) recommended the 
classifications of overweight and obesity as follows: overweight (BMI � 25.0); pre-obese 
(BMI 25.0-29.9); class I obesity (BMI 30.0-34.9), class II obesity (BMI 35.0-39.9), and 
class III obesity (BMI � 40) ( 5). 
Obesity has reached epidemic proportions in the United States and is threatening to 
become a global epidemic ( 6). Data from the latest NHANES conducted in 1999 and 
2000 show that 64.5% of U.S. adults are now overweight, and 30.5% are obese compared 
to only 14.5% in 1980 and 22.9% in NHANES III (1988-1994) (7). The prevalence of 
overweight and obesity has risen dramatically over the past two decades, and the 
increases are continuing. If this trend persists, the entire U.S. adult population could be 
overweight or obese within a few generations (8). This alarming increase is also present 
among the nation's youth: ....... 15% of U.S. children and adolescents are overweight (9). 
Overweight that begins early in life persists into adulthood and increases the risk of 
obesity-related conditions later in life (10). Furthermore, the prevalence has been 
increasing in varying degrees, not only in the United States, but also in Britain and 
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elsewhere in Europe, as well as in countries as diverse as Australia, Brazil, China, 
Mauritius and Western Samoa (5). 
Obesity represents a serious threat to health and quality of life because it is strongly 
associated with an increased incidence of non-insulin-dependent (type II} diabetes 
mellitus, coronary heart disease, hypertension, stroke, dyslipidemia, and several types of 
cancer (1 1 ). Perhaps one of the most dramatic and disturbing findings in the past decade 
was that of Pinhas-Hamiel et al. in 1996 (12). After analyzing 1027 patients aged 0- 19 y 
who were diagnosed with diabetes in Cincinnati, they found a tremendous increase (from 
4% to 33%) in the incidence of type II diabetes in children and adolescents between 1 982 
and 1994. In addition to family history and ethnicity (greater risk in African Americans), 
overweight was identified as a major risk factor for type II diabetes. This study was 
important because it showed that type II diabetes was not necessarily a slowly 
progressing disease that affected adults but, in susceptible individuals, could be 
manifested as early in life as adolescence, and it clearly emphasized overweight as 
substantially more than a body weight issue in children. Other obesity comorbidities 
include osteoarthritis and gout, gallbladder disease, and pulmonary diseases, including 
sleep apnea (1 1 ). Obesity-related diseases cause more than 300,000 deaths annually in the 
US alone (13). 
The epidemic of obesity imposes a heavy burden on the healthcare systems of many 
industrialized countries. Obesity-related morbidity may account for 6.8% of US health 
care costs (14). The US Surgeon General's Report estimates that the economic cost of 
obesity in the United States was about $ 1 17 billion in 2000, including both direct medical 
costs and indirect costs such as lost productivity. 
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Genetic factors appear to play an important role in the regulation of body weight and 
body fat (1 5). However, the current epidemic of obesity appears to be caused largely by 
an environment that promotes excessive food intake and discourages physical activity in 
genetically susceptible individuals (16). Control of portion size, consumption of a diet 
low in fat and energy density, and regular physical activity are behaviors that protect 
against obesity, but it is becoming difficult to adopt and maintain these behaviors in the 
current environment. 
Obesity increases the risk of preventable death by 50% to 150% (17). Weight loss 
itself is likely to be beneficial. Many studies have shown that during periods of weight 
loss there is a uniform improvement in the profile of chronic disease risk factors ( 18, 19). 
A moderate weight loss ( So/()"' 1 0%) in people who were 50% to 100% overweight 
produced significant drops in their blood pressure, blood levels of triglycerides, and 
improved glucose tolerance as well. Moderate weight loss is also associated with 
significant decreases in total cholesterol and increases in high-density lipoprotein (HDL) 
cholesterol levels, and subsequently an improvement in the ratio of total cholesterol to 
HDL cholesterol. In a large 12-yr prospective study of 43,457 overweight middle-aged 
white women, those who intentionally lost weight and also had obesity-related health 
problems had a 20% reduction in all-cause mortality (20). This was primarily due to a 
40% to 50% decline in obesity-related cancers, such as those of the uterus and cervix, as 
well as a 30% to 40% decrease in diabetes-associated mortality. In women with no 
preexisting illness, intentional weight loss of�20 lb was associated with about a 25% 
reduction in all-cause, cardiovascular, and cancer mortality. 
1 1  
Methods for the treatment of obesity include dietary management, physical activity 
and exercise, and antiobesity drugs, with gastrointestinal surgery being reserved for 
extreme cases (1 1). Americans spend about $40 billion per year on weight-loss 
treatments, mostly in the form of diets and dietary foods (17). 
II. Etiology of Obesity 
Obesity appears as a complex multi-factorial disease resulting from a prolonged 
imbalance between energy intake and energy expenditure, especially in genetically 
susceptible individuals (2 1 ). Available evidence suggests that obesity results from 
multiple interactions between genes and environment. Parental obesity is the most 
important risk factor for childhood overweight. Single gene defects leading to obesity 
have been discovered in animals and, in some cases, confirmed in humans as congenital 
leptin deficiency or congenital leptin receptor deficiency. However, in most cases, genes 
involved in weight gain do not directly cause obesity, but instead increase the 
susceptibility to fat gain in subjects exposed to an unfavorable environment such as 
constant access to energy-dense food and minimal physical demands of daily living (22). 
A. Genetic factors 
There is strong evidence that genetic factors contribute to the development of obesity 
in humans as well as laboratory animals. Twin, adoption, and family studies have now 
established that an individual's risk of obesity is increased when he or she has relatives 
who are obese. Other studies have shown consistently that -40 to 70% of the variation in 
obesity-related phenotypes, such as BMI, sum of skinfold thickness, fat mass, and leptin 
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levels, is heritable (23). Human obesity is a polygenic trait, being determined by 
interaction of several "susceptibility" genes, each of which may have relatively small 
effects, with each other as well as with environmental factors such as nutrients and 
physical activity (24). 
1. Genetic influences on obesity in rodent models 
The genes associated with several monogenic defects that produce obesity in 
experimental rodents have been cloned and characterized. These genes and gene products 
reveal novel molecular and biochemical mechanisms underlying the etiology of obesity 
and provide promising targets for therapeutic intervention (25, 26). Several transgenic 
and knockout rodent models that modify body fat provide insight into important systems 
that are involved in the regulation of food intake, fat storage and/or energy expenditure 
(26). The polygenic obese rodent models are excellent models to investigate the genetic 
mechanisms underlying the development of human obesity involved in gene-gene and/or 
gene-nutrient interactions (26). 
a. Single gene defects 
The major monogenic obese rodent models include obese (Lepobloi mouse, diabetes 
(Leprdbldi mouse, Zucker fatty (Lep/alfa) rat, yellow obese (R/a) mouse, fat (Cp/0'1 
Cp/0') mouse and tubby (tub/tub) mouse. Of these, the phenotype of the yellow obese 
(AY/a) mouse is caused by autosomal dominant mutation while the rest are caused by 
autosomal recessive mutations. 
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( 1 )  The obese (Lep0b10°) mouse, diabetes (Lep,-dbld°) mouse and Zucker fatty (Lep,lalfa) rat 
The phenotypic expression of the obese syndrome is similar across the three 
autosomal recessive mutation models. These animals exhibit hyperphagia, morbid obesity 
and type II diabetes, decreased energy expenditure, insulin resistance/hyperinsulinemia 
and reproductive deficiency (27). The obese (Lep0b/0°) mouse and diabetes (Lep,-dbld°) 
mouse are two most widely studied models as the result of Coleman's elegant series of 
parabiosis experiments (28). Lepoblob mice whose peripheral circulation was joined 
surgically with control mice exhibited normalization of body weight. This suggested that 
Lepoblob mice were deficient in a circulating factor, now known as leptin or OB protein, 
which regulated the size of the body fat depot. Alternatively, Lep,-dbldb mice, when linked 
to their lean controls, did not exhibit weight loss, suggesting that Lep,-dbldb mice were 
defective in the receptor for the circulating factor leptin. 
The mouse ob gene, located on mouse chromosome 6, was cloned in 1994 (29). It 
encodes leptin (OB), which contains 167 amino acids. In the obese (Lep0b10°) mouse, a 
single base substitution at codon 105 was identified. This introduces a stop codon, 
resulting in a premature-truncated inactive protein. The mouse db gene is located on 
mouse chromosome 4 and encodes the leptin receptor (OB-R) (30-33). This receptor has 
at least six alternatively spliced forms. OB-RL , the long form OB-R, has a long 
cytoplasmic region containing several motifs required for leptin signal transduction, and 
is expressed at high levels in hypothalamus. The other forms lack some or all of these 
motifs. They are found at high levels in the choroids plexus, thus are speculated to play a 
role in transporting leptin from the blood into cerebral spinal fluid (CSF), where it can 
then move by diffusion to the brain centers that regulate body weight since leptin enters 
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the brain by a specific and saturable transport mechanism (34). In Lep,-dbldb mice, a G� T 
point mutation was identified in the genomic OB-R sequence, which generates a donor 
splice site that converts a 106 nucleotide region with a premature stop codon into a novel 
exon transcript (30). This abnormal splicing resulted in a short form OB-R without the 
long intracellular domain. Thus, the long intracellular domain of OB-R is crucial for 
initiating leptin signal transduction. A similar mutation is thought to be present in Zucker 
fatty (Lep!alfa) rat (35, 36). 
Leptin is produced primarily in white adipose tissue. Both peripheral and central 
administration of recombinant leptin in Lepoblob mice lowered their body weight, percent 
body fat, food intake, concentrations of glucose and insulin; increased metabolic rate, 
body temperature, activity levels; and repaired reproductive function but had no effect on 
Lep,-dbldb mice (3 7-40). Thus, leptin serves an endocrine function to regulate body fat 
stores, and it can act directly on neuronal networks that control feeding and energy 
balance. The hypothalamus is the primary target tissue which leptin act upon to exert its 
energy-regulatory effects (41, 42). Hypothalamic neuropeptide Y (NPY) stimulates food 
intake, decreases thermogenesis and increases plasma insulin and corticosterone levels. 
Leptin has been shown to exert its weight reducing effects via inhibition ofNPY 
synthesis and release (43). Thus, leptin responsive neurons in hypothalamus express 
neuropeptides that are modulated by leptin and interact with each other in controlling 
feeding behavior and energy balance. 
The mouse ob gene is highly homologous with human, monkey and rat ob genes. In 
contrary to the leptin deficiency found in the obese (Lep0b10") mouse, leptin gene 
expression increases with body fat in a range of obese animal models, including the 
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diabetes (Lep,-tlbld") mouse, the Zucker fatty (Lep,lalfa) rat, and rats fed a high-fat diet (44). 
Several studies have examined leptin in a variety of obese and normal humans as well. A 
generally positive correlation between fat mass and leptin levels is observed in 
individuals with extreme obesity, suggesting that leptin deficiency is not a common cause 
of obesity in human populations (45,  46). This has led to the suggestion that human 
obesity may be caused by resistance to leptin action. As mentioned earlier, the transport 
of leptin across the blood/brain barrier may be saturable, as leptin levels in human CSF 
are normally <10% of serum levels (34, 47). Another possibility is that significant 
numbers of humans will have a polymorphism in the OB-R gene, which results in the 
production of receptors with different signaling potency ( 48). More likely, leptin 
resistance may be a result of flaws within the signal-transducing pathway of the leptin 
receptor, more analogous to the mechanism of insulin resistance (33). 
(2) The yellow obese (AY /a) mouse 
Dominant mutations in the mouse agouti gene confer a pleitropic syndrome 
characterized by maturity-onset obesity, mild hyperphagia, decreased thermogenesis, 
hyperinsulinemia, peripheral insulin resistance, impaired glucose tolerance, increased 
linear growth and yellow fur (49, 50). The agouti gene, located on mouse chromosome 2, 
was the first obesity gene cloned and characterized (5 1 ,  52). It encodes a 1 3 1-amino-acid 
protein with a consensus signal peptide. Agouti protein is normally transiently expressed 
in the hair follicle during the mid-portion of the hair growth cycle. It acts to inhibit the 
synthesis of eumelanin, a black pigment, by competitively antagonizing a-melanocyte­
stimulating hormone ( a-MSH) binding to its melanocortin- 1 receptor (MC 1 -R), resulting 
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in a down-regulation of cAMP production and a temporary synthesis of phaeomelanin, a 
yellow pigment. This produces the characteristic pigmentation pattern of wild-type mice, 
a predominantly black hair shaft with a subapical yellow segment (53). In the yellow 
mouse, dominant mutations in promoter regions result in ubiquitous expression of normal 
agouti protein in a wide range of tissues, including white adipose tissue and 
hypothalamus (51), throughout the life of the mouse. Transgenic mice ubiquitously 
expressing agouti driven by the human P-actin promoter also develop yellow coat color 
and become obese (54, 55), confirming that ectopic expression of normal agouti protein 
in the obese yellow phenotype. Interestingly, the human homo log of the agouti gene, 
named agouti signaling protein (ASIP) that is 85% homologous to mouse agouti, is 
expressed primarily in adipose tissue and pancreas (56), suggesting that it may play a role 
in human obesity. 
Although the genetic defect in the agouti yellow mouse syndrome clearly involves 
ectopic expression of the agouti gene, the actual mechanism of the yellow obese 
syndrome is not clear. Both central and peripheral effects of agouti have been explored 
extensively (57). Agouti is a potent antagonist of the melanocortin-4 receptor (MC4-R), a 
related MSH-binding receptor MCl-R (58, 59). MC4-R is widely expressed throughout 
the brain, with a high degree of expression in hypothalamus centers involved in appetite 
and body weight regulation (60). Intracerebroventricular administration of a potent MC4-
R agonist inhibited food intake in four murine models of obesity and hyperphagia while 
co-administration of the specific MC4-R antagonist completely blocked this inhibition 
(61). Further, MC4-R knockout mice exhibit adult-onset obesity associated with 
hyperphagia, hyperinsulinemia and insulin resistance, recapitulating many of the 
17 
metabolic features of the yellow obese mouse (62). Thus, the chronic antagonism of 
MC4-R may be responsible for the development of the yellow mouse obesity. An 
accumulating body of evidence ( 63-70) indicates that peripheral actions of agouti are 
likely to contribute to agouti-induced obesity as well, and strongly suggest a role of 
agouti signaling in adipocytes and pancreatic J3-cells through its ability to increase 
intracellular Ca2+ ([Ca2+]i) levels, and consequently stimulate triglyceride storage and 
inhibit lipolysis, as discussed in detail later. 
The yellow mouse exhibits maturity-onset obesity, which is primarily due to 
increased metabolic efficiency, with a preferential partitioning of food energy into fat 
storage (57). Yellow mice exhibit increases in the expression and activity of lipogenic 
enzymes in both liver and adipose tissue ( 66, 71 ). Further, lipolysis is reduced in adipose 
tissue of yellow mice compared to wild-type mice and the lipolytic response to 
epinephrine is suppressed as well (72). Thus, the coordinated augmentation of 
lipogenesis and inhibition of lipolysis observed in these mice may contribute to the 
increase in metabolic efficiency. Given the role of insulin in promoting nutrient 
partitioning into adipose tissue, hyperinsulinemia may contribute to the enhanced 
metabolic efficiency of yellow mice (57). There is positive correlation between weight 
gain and insulinemia and between insulin levels and lipogenic enzyme activity in obese 
yellow mice (71 ). However, hyperinsulinemia is not sufficient to produce the obesity in 
the absence of agouti expression. Transgenic mice expressing agouti at high levels in 
adipose tissue under the control of the adipose tissue-specific fatty acid-binding protein 
aP2 promoter ( aP2-agouti transgenic mice) become obese if they are also 
hyperinsulinemia while hyperinsulinemia was without effect in non-transgenic littermate 
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controls (73). In fact, agouti and insulin appear to exhibit a synergistic interaction, which 
\ 
results in the development of obesity (74, 75). Recent data indicate that these effects are 
mediated by modulation of [Ca2+]i (63-70). 
(3) The fat ( Cp/01/Cp/01) mouse 
The fat mouse exhibits progressive adult-onset obesity and is characterized by 
massive hyperinsulinemia (76). The apparent hyperinsulinemia was in fact a 
hyperproinsulinemia (77). The fat gene, located on mouse chromosome 8, has been 
shown to encode carboxypeptidase E (CPE), which is required for cleavage of two 
arginine residues from the B chain of insulin during its processing from proinsulin. In 
addition to proinsulin, a number of prohormones and proneuropeptides, including pro­
opiomelanocortin (POMC), also require cleavage of paired dibasic residues from their C­
terminal ends to yield the biologically active peptides. POMC is a precursor for peptides 
such as adrenocorticotropic hormone (ACTH) and MSH, and MSH is known to act on the 
melanocortin receptor family involved in the control of feeding (78). In the fat mouse, a 
single base mutation that results in a serine to proline substitution at position 202 severely 
reduces the amount and activity of CPE in both the pancreatic islet and pituitary (77). As 
CPE is expressed in central nervous system (CNS), the obesity phenotype of fat mouse is 
likely to result from defects in the production and activity of neuropeptides such as 
POMC in hypothalamus (77-79). 
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(4) The tubby (tub/tub) mouse 
Homozygous mice with a mutation at the tub locus develop late-onset obesity and 
insulin resistance (76, 80). The tubby gene, located on mouse chromosome 7, was cloned 
in 1996 (80, 81 ). In tub/tub mouse, a single base mutation of G-+ T within a splice donor 
site in the 3' coding region abolishes the donor splice site and results in a larger transcript 
containing the unspliced intron. The consequence of this mutation is the substitution of 
the 44-carboxy-terminal amino acids with a 20-amino-acid sequence not found in the 
wild-type protein. It was shown that tubby proteins localize to the plasma membrane by 
binding phosphatidylinositol 4, 5-bisphosphate through its carboxyl terminal "tubby 
domain", and function as membrane-bound transcription factors that translocate to the 
nucleus in response to receptor-mediated activation of GTP-binding protein (G protein) 
(82). The normal tubby proteins appear to be abundantly expressed in the hypothalamus, 
suggesting that obesity in the tubby mice may stem from malfunction of signaling 
pathways in the satiety center (81 ). 
b. Transgenic and knockout rodent models of obesity 
Table 1 lists several transgenic and knockout rodent models that have been shown to 
modify body fat. Each of these transgenic animals provides some insights into important 
systems that are physiologically perceived to be involved in the regulation of food intake, 
fat stores and energy expenditure. 
Available evidence indicates that the hypothalamic-pituitary-adrenal axis (HP A) 
plays a key role in the control of energy balance in laboratory rodents (83). Transgenic 
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Table 1. Transgenic and Knockout Rodent Models of Obesity 
Gene Tg or KO• Major tissues Phenotypes References 
Tg CNS-, testis, heart, Cushing' s syndrome 84 
adrenal gland 
KO CNS, liver Impaired GCR function; obesity 85 
Tg AT• Obesity due to adipocyte hyperplasia; 9 1  
enhanced glucose disposal 
Agouti Tg Ubiquitous Reproduced phenotype 55 
of AY/a obese yellow mice 
Tg AT Become obese if hyperinsulinemia 73 
KO CNS Recapitulated features 62 
of AY/a obese yellow mice 
KO CNS Obesity, hyperphagia; adrenal 92 
Insufficiency; altered pigmentation 
UCPI-DTA• BAT• Obesity with hyperphagia; ablated BAT; 96 
expression impaired BAT thermogenesis 
KO BAT Cold-sensitive but not obese 10 1  
KO AT, SM., Not obese, not cold-sensitive; 1 1 5 
immune system macrophages generate more 
ROS; resistant to infection 
Tg normal rat Impaired glucose-stimulated 1 1 8 
pancreatic islets insulin secretion 
Tg ZDF ra( Enhanced insulin secretion 1 19 
pancreatic islets 
ucp3• Tg SM Hyperphagic but lean; increased 107 
resting metabolic rate; improved 
insulin sensitivity 
KO AT, SM Not obese; more coupled; 108 
increased production of Ros· 
KO AT Modest obesity 132 
13-ARs· KO AT Massive obesity during overfeeding 
due to failed DIT• 
133 
* Tg: transgenic; KO: knockout; CRH: corticotropin-releasing hormone; CNS: central nervous system; 
GCR: glucocorticoid receptor; GLUT4: GLUT 4 glucose transporter; AT: adipose tissue; MC4-R: 
melanocortin-4 receptor; POMC: pro-opiomelanocortin; UCPl-3 :  uncoupling protein 1-3 ;  OTA: diphtheria 
toxin A-chain; BAT: brown adipose tissue; SM: skeletal muscle; ZDF rat: Zucker Diabetic Fatty rat; ROS: 
reactive oxygen species; �3-AR: �3-adrenergic receptor; �-ARs: � 1, �2, �3-adrenergic receptors; DIT: diet­
induced thermogenesis 
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mice overexpressing the corticotropin-releasing hormone (CRH) gene under control of 
the metallothionein promoter exhibit endocrine abnormalities involving the HP A axis, 
such as elevated plasma levels of ACTH and glucocorticoids (84). These animals display 
features of Cushing's syndrome with truncal obesity, decreased linear growth, marked 
bilateral hair loss, muscle wasting and reduced fertility. 
The type II glucocorticoid receptor (GCR) is involved in glucocorticoid negative­
feedback effects on the HP A axis activity. Barden et al (85) incorporated a type II GCR 
antisense RNA construct into mice. The transgenic mice had greatly increased fat 
deposition and, at -6 months of age, were twice the weight of normal mice. Northern blot 
analysis of endogenous type II GCR mRNA indicates a maximal 50-70% decrease in 
hypothalamus and cerebral cortex, and a smaller 30-55% decrease is seen in liver. The 
transgenic mice also have a reduced GCR binding activity for glucocorticoids with raised 
serum ACTH and glucocorticoids concentrations due to a failure of glucocorticoids to 
inhibit HP A axis activity. Glucocorticoids can decrease the number of GCRs in both 
hypothalamus and pituitary glands, and the high glucocorticoid levels in transgenic mice, 
secondary to decreased type II GCR levels, could be an additional factor in 
downregulating the type II GCR even further compared with antisense RNA (85). This is 
consistent with previous studies emphasizing the dependence of all obesities on the 
presence of adrenal glucocorticoids in a wide range of animal models, including the 
genetically obese Lep/alfa rats, Lepoblob, Lep/bldb, and AY/a mice. Bilateral adrenalectomy 
prevents, attenuates or reverses the development of obesity in these animals (86-89), 
suggesting that glucocorticoids are required for the phenotypic expression of genetic 
obesity. 
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The GLUT 4 glucose transporter plays a pivotal role in insulin-stimulated glucose 
transport in adipose tissue and muscle (90). Overexpression of GLUT 4 in white adipose 
tissue (6-9-fold) and brown adipose tissue (3-5-fold) using the aP2 promoter/enhancer 
increased total body lipid 2-3-fold (91). This was associated with a massive increase in 
the basal transport of glucose into adipocytes and, interestingly, a twofold increase in fat 
cell number, but no increase in fat cell size. This provided the first model of obesity 
associated with hyperplastic growth of adipose tissue in the absence of cell hypertrophy. 
Thus, it is a valuable model for understanding the mechanisms responsible for adipocyte 
replication and/or differentiation in vivo. 
Mice in which the POMC gene has been inactivated exhibit obesity and hyperphagia. 
The mice also exhibit adrenal insufficiency owing to a lack of ACTH, and altered 
pigmentation owing to a lack of MSH (92). The mice exhibit a phenotype that is 
essentially identical to that observed in humans with inactivating mutations in the gene 
encoding POMC (93). This model will undoubtedly prove useful in determining the roles 
of the individual cleavage products of POMC on energy homeostasis. 
Uncoupling protein-1 (UCPl) is a mitochondria proton transporter expressed 
exclusively in mammalian brown adipose tissue (BAT). UCP 1 dissipates the proton 
electrochemical gradient across the mitochondria membrane, thereby uncoupling 
substrate oxidation from conversion of ADP to ATP, leading to generation of heat and 
thus increased energy expenditure (94, 95). As BAT and UCPl are abundant in rodents, 
BAT thermogenesis may be important in the regulation of energy expenditure in rodents. 
Dysfunction of BAT could lead to decreased energy expenditure and could play a critical 
role in the pathogenesis of obesity in rodents. Indeed, Lowell et. al created transgenic 
23 
mice in which the UCP 1 promoter drives BAT specific expression of diphtheria toxin A­
chain (UCP-DTA), thus causing primary deficiency of BAT (96). In these transgenic 
mice, both UCP 1 content and BAT was markedly decreased. Correspondingly, BAT 
thermogenic function was abolished in response to both cold and CL3 l 6,243, an 
extremely selective �3-adrenergic receptor agonist. Moreover, these mice became obese 
and developed hyperphagia, illustrating the possible link between BAT thermogenic 
function, food intake and obesity in rodents. Interestingly, hyperphagia and obesity are 
absent when UCP-DTA mice are reared at thermoneutrality, which indicates that even in 
this model, there is no obesity without hyperphagia (97). Bray et al. demonstrated a 
highly significant inverse relationship between spontaneous electrical activity of 
sympathetic nerves innervating BAT and food intake in spontaneously feeding rats, 
suggesting the reciprocal relation between BAT thermogenesis and food intake (98, 99). 
Accordingly, Himms-Hagen proposed a thermoregulatory feeding hypothesis (100). That 
is, the initiation of feeding occurs during an episode of increased sympathetic nervous 
system activity that stimulates BAT thermogenesis and increases body temperature. Once 
body temperature increases to a certain level, the feeding terminates. Thus, BAT 
thermo genesis is important in control of meal size and satiety. When this function is lost, 
the animal loses its ability to control meal size, and hyperphagia and obesity occur 
subsequently. 
Contrary to this thermoregulatory feeding hypothesis is another study conducted by 
Enerback et al., demonstrating that mice lacking mitochondria UCPl are cold-sensitive 
but not hyperphagia and obese (101). UCPl knockout (KO) mice were generated by 
target inactivation ofUCPl gene. The BAT ofUCPl KO mice has enlarged lipid 
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vacuoles but in all other respects it appears normal. The oxygen consumption after 
treatment with CL316,243 was significantly blunted in UCP 1 KO mice compared to 
wild-type mice, like that found for UCP-DTA mice. UCPl KO mice are more cold­
sensitive than UCP-DTA mice, indicating that their thermoregulation is defective. As it is 
assumed that a role for BAT in energy balance is determined by UCP 1-derived 
thermogenesis, UCPl KO mice should be as, or more obese than, UCP-DTA mice. 
Unexpectedly, the knockout of UCP 1 caused neither hyperphagia nor obesity in mice fed 
on either standard or a high-fat diet. To explain this unexpectancy, the investigators 
proposed that an alternative mechanism for maintaining body mass must exist that cannot 
protect against the cold. They found that UCP2, a recently discovered homologue of 
UCPl, was up-regulated fivefold in the BAT ofUCPl KO mice. Thus, UCP2 may 
compensate for the loss of UCPl to maintain normal body mass without protecting 
against cold. 
Taken these studies together, UCP 1 is important for thermogenesis while BAT plays 
a critical role in the regulation of energy balance in mice, and that BAT deficiency can 
cause obesity. 
UCP2 (102, 103) and UCP3 (104, 105) are more recently discovered members of the 
mitochondria inner membrane transporter family with high homology (59% and 57%, 
respectively) to the BAT-specific UCPl. UCP3 is expressed primarily in skeletal muscle 
and BAT while UCP2 is widely expressed but at varying levels in a number of tissues 
and cell types including skeletal muscle, BAT, WAT, brain, lung, heart, kidney, placenta, 
spleen, leukocytes, macrophage etc. Both in vitro and in vivo studies support the 
uncoupling activity of these proteins indicated by high proton leak and low mitochondria 
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membrane potential (102, 103, 106-108). However, their physiological roles are 
unknown. It is well established that BAT is an important tissue for thermogenesis in 
rodents. However, in large mammals in which BAT is less common, skeletal muscle may 
be more important for thermo genesis (109). Thus, based upon their high homology with 
UCP-1 and their tissue distribution in skeletal muscle and adipose tissue, UCP2 and 
UCP3 have been suggested to play important roles in regulating energy expenditure, 
body weight and thermoregulation (102, 105). UCP2 and UCP3 are also implicated in the 
regulation of lipids as fuel substrate in skeletal muscle on the basis that their mRNA 
expressions are up-regulated during starvation (when fat stores are being rapidly 
mobilized) and down-regulated during the early phase of re-feeding (when fat stores are 
being rapidly replenished) (110, 111). These starvation/re-feeding studies suggest that 
UCP2 and UCP3 may function as regulators of lipids as fuel substrate rather than as 
mediators of regulatory thermo genesis. It has also been proposed that UCP2 and UCP3 
could prevent the formation of oxygen-free radicals in skeletal muscle. Several studies 
show that reactive oxygen species (ROS) production is a function of the mitochondria 
membrane potential. It has been hypothesized that ROS are produced when the 
mitochondria membrane potential is above a specific threshold. Mild uncoupling of the 
mitochondria could be a mechanism to prevent the formation of ROS (112-114). This 
mechanism could be important in skeletal muscle, given that it accounts for an important 
fraction of the total oxygen consumption at rest and that this fraction is even higher when 
skeletal muscle switches to maximal activity. Thus, one of the functions ofUCP 2 and 
UCP3 could be to prevent excessive oxidative stress in skeletal muscle (1 08). In 
summary, the information available about the physiological role of UCP2 and UCP3 is 
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still controversial and incomplete. To further illustrate the physiological function of these 
two uncoupling proteins, both overexpression and knockout rodent models have been 
generated. 
Clapham et al. created transgenic mice that overexpress human UCP3 driven by a.­
skeletal actin promoter in skeletal muscle (107). These mice are hyperphagic but weigh 
less than their wild-type littermates. Magnetic resonance imaging shows a striking 
reduction in adipose tissue mass. This phenotype is associated with increased resting 
metabolic rate as measured by 25% to 40% higher resting oxygen consumption than the 
wild-type littermates. The mice also exhibit lower fasting plasma glucose and insulin 
levels and an increased glucose clearance rate, indicating improved insulin sensitivity. 
This provides evidence that skeletal muscle UCP3 has the potential to influence 
metabolic rate and glucose homeostasis in the whole animal, suggesting that 
enhancement of UCP3 expression or stimulation of its activity is a promising approach 
for the treatment of obesity. 
Vidal-Puig et al generate UCP3 gene knockout (KO) mice using a gene targeting 
approach (108). These mice do not develop obesity. They found that skeletal muscle 
mitochondria lacking UCP3 are more coupled, indicating that UCP3 has uncoupling 
activity. They also found that there is increased production of ROS in skeletal muscle 
mitochondria lacking UCP3. They then demonstrate that UCP3, expressed at endogenous 
levels, has uncoupling activity and its absence may lead to increased production of ROS, 
consistent with the hypothesis that UCP3 may function to prevent excessive oxidative 
stress in skeletal muscle. Their data also show that UCP3 does not seem to be required 
for normal body weight regulation. This observation may not be completely surprising, 
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since the genetic disruption of UCPl did not result in obesity (101). However, unlike 
UCPl KO mice, mice lacking UCP3 are not cold sensitive, and they do not have up­
regulation of either UCP2 or UCPl mRNAs. These suggest that UCP3 may not play an 
important role in regulating body weight or adaptive thermogenesis in response to cold 
exposure. However, it can not be excluded that the lack of UCP3 activity could be 
compensated through post-translational activation of UCP2 and/or UCPl activity or, 
alternatively, through activation of other unknown futile cycles. Thus double and triple 
UCP KO mice would be useful tools to address these questions. 
Similarly, Mice lacking UCP2 following targeted gene disruption are not obese and 
have a normal response to cold exposure or high-fat diet (115). Moreover, they are 
completely resistant to infection, in contrast with the lethality observed in wild-type 
littermates. Macrophages from UCP2 KO mice generated more ROS than wild-type 
mice, indicating a role for UCP2 in the limitation of ROS and macrophage mediated 
immunity. Since there are high levels of UCP2 mRNA expression in organs of the 
immune system such as spleen, lung and macrophages (102, 103), a role for UCP2 in 
immunity or inflammatory responsiveness makes sense. The authors also found increase 
of UCPl mRNA expression in WAT. Increase of UCP2 mRNA was previously noted in 
BAT of mice deficient for UCPl (101). Thus, this study suggests that UCPl, but not 
UCP2, may play a critical role in both cold- and diet-induced thennogenesis and 
regulation of body weight. UCP2 may be important to limit ROS production by its mild 
uncoupling activity. Between UCP2, immunity and ROS, UCP2 KO mice now provide a 
new tool to further elucidate molecular mechanisms of resistance to infection. 
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UCP2-overexpressing rats were used to understand the relationship between UCP2 
and �-cell insulin secretion. As UCP2 rat homolog is present in pancreatic islets, among 
other tissues (116, 117), two different groups created rats overexpressing UCP2 in 
pancreatic islets. Chan et al. overexpressed human UCP2 in normal rat islets by infection 
with an adenovirus (AdEGI-UCP-2) (118). The mice exhibited severe blunting of glucose 
stimulated insulin secretion (GSIS), illustrating a direct, causal relationship between 
overexpression of UCP2 and inhibition of GSIS in normal islets. The mechanism by 
which UCP2 affects insulin secretion is predicted to be via decreasing cellular ATP 
content. However, in another study conducted by Wang et al. , UCP2 overexpression in 
islets of Zucker Diabetic Fatty (ZDF) rat reduced �-cell ATP but increased the ATP/ADP 
ratio and enhanced insulin secretion in ZDF rat islets (119). Thus, results to date in 
normal and ZDF rats appear contradictary, but a possible mechanism for reduction of 
GSIS during starvation and type II diabetes might include upregulation of UCP2 
expression (120). 
The sympathetic nervous system (SNS) influences many physiological functions 
including body temperature homeostasis and lipid metabolism by releasing the 
neurotransmitter norepinephrine that acts upon �-adrenergic receptors (�-ARs)(121). All 
three known subtypes of �-ARs, namely �1-, �2- and �3-AR, are expressed in both WAT 
and BAT. They all couple via Ga-protein to adenylate cyclase (AC), leading to an 
increase in cAMP. The resulting activation of protein kinase A (PK.A) mediates the major 
actions of these receptors that include stimulation of lipolysis in white adipocytes and 
thermogenesis in brown adipocytes (122). 
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p3-ARs are expressed predominantly in WAT and BAT in mice (123, 124). 
Moreover, a number of in vivo studies have provided clues regarding the possible 
physiological significance of P3-ARs. In genetically obese Lep,Jalfa rats (124) and Lep0blob 
mice (125), p3-ARs mRNA levels are significantly down-regulated, raising the possibility 
that decreased p3-ARs function might contribute to the development of obesity in these 
animals. Selective activation of P3-ARs leads to marked increases in triglyceride 
breakdown (lipolysis) and energy expenditure as measured by effects on oxygen 
consumption, and long-term treatment of obese rodents with P3-selective agonists reduces 
fat stores and improves obesity-induced insulin resistance (126-128). Of note, it has been 
reported that a missense mutation of the human p3-ARs tends to be associated with 
obesity, decreased energy expenditure, reduced insulin sensitivity and earlier onset of 
type II diabetes (129-131). These observations suggest that P3-ARs might also play an 
important role in humans as well. Thus, P3-ARs represent one of a number of potential 
anti-obesity drug targets (126-128). Susulic et al. generated P3-AR-knockout mice (P3-
KO) by direct injection of a DNA targeting construct into mouse zygotes ( 1 32). The (33-
KO mice had normal body weight compared to wild-type mice, although they do exhibit 
modestly increased fat stores (females more than males). Interestingly, fed insulin and 
glucose levels and food intake are unchanged in the p3-KO mice, indicating that 
compensatory mechanisms might operate in these animals to maintain normal energy 
homeostasis. In fact, the expression of P 1-AR mRNA is upregulated in WAT and BAT in 
these animals. Finally, acute treatment of normal mice with CL316,243, a selective P3-
agonist, increased serum levels of free fatty acids (FF As) (3 .2-fold) and insulin ( 140-
30 
fold), increased energy expenditure (2-fold) and reduced food intake (by 45%). However, 
these effects were completely absent in �3-KO mice, proving that the actions of CL are 
mediated exclusively by �3-AR. Thus, this �3-KO mouse model should be useful as a 
means to a better understanding of the physiology and phannacology of �3-ARs. 
Recently, Bachman et al. created mice lacking all three �-ARs (�-less mice) and 
provided direct evidence that the SNS and the �-AR signaling pathways are necessary for 
diet-induced thermogenesis (DIT) (1 33). Previous overfeeding experiments indicated that 
humans vary in their capacity to resist weight gain because of varying abilities to convert 
food directly into heat, a process called DIT (1 34). Further, Landsberg et al. 
demonstrated that SNS activity in a variety of tissues is boosted during overfeeding and 
decreased during starvation (a state of energy conservation), suggesting the SNS as the 
efferent system linking diet and thermogenesis ( 1 35). Bachman et al. showed that the �­
less mice on a Chow diet had a reduced metabolic rate and were slightly obese. On a 
high-fat diet (58% of kcal from fat), the �-less mice could not increase thermogenesis and 
· became massively obese. In contrast, the wild-type mice are able to resist obesity during 
overfeeding by activating DIT. Thus, �-less mice have a failure of DIT. In addition, the 
(3-less mice are also intolerant to cold exposure, suggesting that the SNS-(3-AR pathway 
control heat production in response to both diet and cold. BAT, because of its UCPl­
mediated uncoupling of respiration and its intense sympathetic innervation, is thought to 
be the source of DIT. Indeed, BAT in �-less mice was unresponsive to both physiological 
( cold exposure) and phannacological (�-agonist) stimulation. Compared to wild-type 
mice, BAT in �-less mice expressed lower levels of UCPl at room temperature and failed 
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to induce UCPl expression after cold exposure. A maximally effective dose of 
isopreterenol, a nonselective J3-agonist, stimulated oxygen consumption in wild-type 
mice more than twofold but had no effect in J3-less mice. Thus, J3-ARs are necessary for 
normal BAT function. Both supporting and opposing evidence exist regarding the role of 
BAT in DIT. Transgenic mice in which UCPl promoter. drives BAT specific expression 
of diphtheria toxin-A (UCPl-DTA), which have markedly ablated BAT, are obese and 
sensitive to DIT (96). However, UCPl gene-knockout (UCPl KO) mice, although 
showing greatly impaired cold-induced thermogenesis, are neither obese nor sensitive to 
diet-induced obesity (101). Thus, UCPl is required for cold- but not diet-induced 
thermogenesis whereas J3-ARs are required for both. In summary, the J3-less mouse model 
indicates that J3-ARs are necessary for DIT and that the SNS-J3-AR pathway plays a 
critical role in the body's defense against diet-induced obesity. 
c. Polygenic models of obesity 
The polygenic forms of obesity, which are normally of later onset and sometimes are 
less severe, are often influenced by gene-gene and/or gene-diet interactions ( 44). The two 
most studied polygenic mouse models are the AKR mouse model and the BSB mouse 
model (26). Inbred mouse strains, produced by 20 or more generations of brother x sister 
matings, provide the basic resource for analysis of multigenic traits (136). West et al. 
developed and characterized a polygenic model of differential susceptibility to dietary 
obesity in the inbred mouse strains ( 13 7). The AKR/J strain of inbred mouse becomes 
significantly obese when fed a high-fat diet while the SWR/J strain remains relatively 
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lean. Intercrosses between these two strains segregate the phenotype of sensitivity to 
dietary obesity, thus provides a useful tool to pursue the metabolic and genetic basis of 
this trait under the influence by gene-diet interaction. The BSB mouse model is derived 
from C57BL/6J mice crossed with Mus spretus and the Fl mice subsequently 
backcrossed onto the C57BL/6J strain (138). A significant percentage of the mice in the 
backcross generation become obese spontaneously on a low-fat diet with a body fat 
content that shows individual variation from 1 % to 50% while neither of the parental 
strains demonstrate spontaneous obesity, suggesting that obesity may result from the 
interactions of two genes. 
Quantitative trait loci (QTL) mapping is now a general technique to map all of the 
genes underlying any complex trait such as obesity by using polymorphic genetic 
markers covering the whole mouse genome (136). The QTL approach involves the 
crossing of two strains that differ in the trait of interest to produce F2 or back-cross 
progeny, individually phenotyping and genotyping each progeny for markers that are 
spread throughout the genome. Then statistical association of markers and phenotypes are 
performed to identify loci underlying the trait of interest (136). Warden et al. have 
applied QTL mapping to spontaneous obesity in the BSB mouse model, with 
identification of loci promoting obesity on chromosomes 6, 7, 12 and 15 (139, 140). West 
et al. have also used QTL mapping to identify loci underlying diet-induced obesity in an 
F2 cross between mouse strains SWR/J and AKR/J, with identification of loci linked to 
adiposity on chromosomes 4, 9 and 15 (141, 142). So far, over 70 loci for polygenic 
obesity have been identified from more than 15 different crosses (143). 
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Since human obesity is polygenic, these polygenic animal models may be used to 
investigate the genetic mechanisms underlying the development of human obesity 
involved in gene-gene and/or gene-nutrient interactions. 
2. Genetic influences on obesity in humans 
There is strong evidence for a genetic component to human obesity. Studies have 
shown that the prevalence of obesity is 2 to 8 times higher in families of obese 
individuals than in the population at large, and that the familial risk increases with the 
severity of obesity. Heritability estimates tend to be highest when derived from twin 
studies (50% to 80%) while they are the lowest when derived from adoption studies (10% 
to 30%) (144). Several studies have reported the presence of major gene effects for BMI, 
body fat and abdominal visceral fat (24). 
Monogenic obesity has been described in a few families due to mutations in leptin 
(145, 146), leptin receptor (147), CPE (148), POMC (93), MC4-R (149-151), 
prohormone convertase 1 (PCl) (152) or PPARy (153). For instance, two children with 
homozygous mutations for loss of leptin function exhibit phenotypes of morbid obesity 
and hyperphasia (145, 146). Another two children with loss of function mutations in 
POMC gene exhibit impaired melanocortin signaling and display obesity and altered 
pigmentation phenotypes (93). Finally, several groups have reported MC4-R mutations 
(149-151). The metabolic phenotypes caused by MC4-R mutations in humans are similar 
to those caused by impaired melanocortin signaling in mice. Although single gene 
mutations as causes of obesity in humans is rare, these mutations confirm that these gene 
products play a role in human obesity and may allow further elucidation of their signal 
transduction pathways. Several groups have searched for linkage between obesity-related 
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phenotypes and the chromosomal region encompassing leptin protein; a meta-analysis 
suggests that there may be linkage with BMI (1 54). 
The role of genetic factors in common human obesities is complex, being determined 
by interaction of several susceptibility genes (polygenic ), each contributing only small 
fraction to the overall susceptibility to obesity, with each other and with environmental 
factors such as diet and physical activity (24). This makes the search of human obesity 
genes a very challenging task. Two strategies, the QTL mapping approach and the 
candidate gene approach, are now used to identify human obesity genes (23 ). 
The role of a genetic predisposition to obesity affects both energy intake and energy 
expenditure. An update of the genetics of human obesity revealed that putative loci 
affecting obesity-related phenotypes are found on all but chromosome Y of the human 
chromosomes, and the numbers of genes and markers that have been linked with human 
obesity are increasing rapidly and now approach 200 (155). Some genes are involved in 
food intake control (NPY, leptin, POMC, cholecystokinin, melanin-concentrating 
hormone etc.) or the regulation of energy expenditure and thermogenesis (�-2 and �-3 
adrenergic receptors, UCP 1-3, leptin etc.), while the expression of some others influence 
different signaling pathways, adipogenesis etc. (PPARy, aP2, PK.A, CCAAT-enhancer 
binding protein etc.), affecting the energy balance (155). 
The possible physiological mechanisms through which a genetic susceptibility may 
be operating include low resting metabolic rate, low rates of oxidation, low fat-free mass 
and altered food intake, as well as other factors related to macronutrient utilization, 
energy expenditure or the hormonal profile, including insulin sensitivity (156). For 
example, UCP2/UCP3 polymorphisms may produce variability in metabolic rates, 
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thereby producing susceptibility or resistance to obesity (157, 158). Studies of 640 
French Canadians and 790 Pima Indians showed that certain DNA sequences that flank 
the UCP2 gene are found primarily in people with low metabolic rates . 
With the publication of the Human Genome, it is likely that our understanding of the 
genetic basis and the identification of novel genes involved in obesity will be greatly 
improved. New pathways in the etiology of obesity will be uncovered, and in the more 
distant future individual identification of genetic variants will be possible, making 
individually targeted therapies available (159). 
B. Environmental factors 
On the simplest level, obesity can arise only when energy intake exceeds energy 
expenditure. The primary environmental factors contributing toward constant positive 
energy balance are high calorie intake and low levels of physical activity (160). Our 
current environment is characterized by nearly unlimited supply of convenient, relatively 
inexpensive, highly palatable, energy-dense foods, coupled with a lifestyle requiring only 
low levels of physical activity for living. Such an environment promotes high-energy 
intake and low energy expenditure (16). Egger & Swinbum described our present 
westernized environment as an 'obesigenic environment' (161). 
1. Diet 
a. High-fat diets 
In W estem societies, high consumption of dietary fat has been linked to a number of 
adverse health outcomes, including cardiovascular disease, some forms of cancer and 
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obesity (162). Considerable evidence from animal studies, carefully controlled laboratory 
studies, cross-sectional studies, clinical trials and studies in individuals at high risk to 
develop obesity clearly demonstrated that consumption of a high fat (HF) diet (�35% of 
energy from fat) increases the likelihood of obesity and that the risk of obesity is low in 
individuals consuming low fat (LF) diets (<20% of energy from fat) (163). 
Obesity is rare in experimental animals maintained on a LF diet, even when they are 
housed in small cages that limit physical activity. In contrast, providing sedentary 
animals with ad /ibitum HF diets reliably produces increases in energy intake, increases 
in efficiency of body fat gain, and obesity (164, 165). Dietary obesity can be reversed by 
switching rodents from a HF to a LF diet, but the extent to which this occurs depends on 
the severity and duration of the dietary obesity (166). 
In numerous human studies, total energy intake was higher when subjects consumed 
diets relatively high in fat than when they ate lower fat diets (167-169). Moreover, body 
fat storage occurs at a greater rate when excess energy comes from fat than when it 
comes from carbohydrate or protein (170). On the other hand, populations consuming 
very-low-fat diets usually do not show high rates of obesity prevalence. A review of the 
results from 28 clinical trials that studied the effects of a reduction in the amount of 
energy from fat in the diet showed that a reduction of 10% in the proportion of energy 
from fat was associated with a reduction in weight of 16 gld (171). This is consistent with 
another behavioral study indicating that dietary restraint provides protection against the 
obesity-promoting effect of the high-fat, high-energy density diet (172). Additional 
support for the role of LF diets in regulating body weight comes from studies of formerly 
obese individuals, a group considered to be at high risk for weight regain. After weight 
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loss induced by an energy-restricted diet, weight regain at 2 yr was less in subjects 
assigned to an ad libitum LF diet ( 5 .4kg) than those consuming a fixed energy intake diet 
(11.3kg) (173). Finally, subjects in the National Weight Control Registry, a database of 
over 2000 individuals successfully maintaining a weight loss of at least 30 pounds for at 
least 1 yr, report eating a diet low in fat and participating in very high levels of physical 
activity (174). 
Our current food supply is high in fat and HF diets promote obesity by increasing 
energy intake, thus, increasing the probability of positive energy balance and weight gain. 
However, the apparent effect of fat per se on energy intake in most studies is difficult to 
separate from an effect of energy density. Since HF foods have a higher energy density 
than LF foods, it is possible that the energy density of the diet rather than the dietary fat 
was responsible for the increased energy intake (16). This hypothesis is supported by 
several studies indicating that when the fat content but not the energy density of diets 
varied, fat content did not affect energy intake (175, 176). Conversely, when energy 
density was manipulated independent of fat content, energy density directly influenced 
energy intake (177-179). Although there remains controversy over the effects of dietary 
fat content on energy intake, considering the fact that not all energy-dense foods are high 
in fat, few HF foods are low in energy density, reductions in dietary fat may still be the 
most effective means of reducing the dietary energy density, and subsequently the 
likelihood of excessive energy consumption (16). 
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b. Portion size 
Accumulating evidence suggest that larger food portion sizes may contribute to the 
increasing prevalence of overweight and obesity ( 16, 180, 181 ). Marketplace food 
portions have increased in size and now exceed federal standards. Portion sizes began to 
grow in the 1970s, rose sharply in the 1980s, and have continued in parallel with 
increasing body weights (181). This growing trend toward larger portions is especially 
evident in fast food restaurants where "supersizing" of menu items is commonplace (16), 
and in buffet restaurants where people tend to consume larger portion sizes (180). 
2. Physical activity 
Three major components of energy expenditure that may influence body weight and 
composition have been identified: basal metabolic rate (BMR), thermic effect of food and 
energetic cost of physical activity (182). Thus, most available evidence suggests that low 
levels of physical activity are associated with an increased risk of obesity (183). The First 
National Health and Nutrition Examination Survey (NHANES I) carried out between 
1971 and 1984 in 8300 individuals showed that low levels of physical activity in the 
intervening 10-year period were associated with weight gains, and recreational activities 
were inversely correlated with body weight (184). 
Our current environment tends to discourage physical activity (16). Advances in 
technology and transportation have reduced the need for physical activity in daily life. 
The appeal of television, electronic games and computers has increased the time spent in 
sedentary pursuits among children and adults. Facilitating this trend is the fact that most 
children in the United States do not engage in daily physical activity at school. 
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Cross-sectional data have often found associations between leisure-time physical 
activity (inverse) or total amount of time spent sitting down (direct) and BMI (182). Data 
from the Seven Countries Study indicated that at the population level job-related physical 
activity is an important determinant of subscapular skinfold thickness (185). In a sample 
of 4063 children aged 8-16 y from NHANES III (1988-1994), boys and girls who 
watched � 4h of television/d had the highest skinfold thicknesses and the highest BMis, 
highlighting the importance of inactivity ( as measured by television viewing) in the 
etiology of overweight (186). Sedentary lifestyle or physical inactivity is accompanied by 
a low fat oxidation rate in muscle and a low fat oxidation rate is a risk factor of fat gain or 
fat re-gain after weight loss (22). Moreover, data from measuring total energy 
expenditure in Mexican and USA Pima Indians support a significant role for physical 
activity in the prevention of obesity in genetically susceptible populations (187). Finally, 
prospective studies provide additional evidence to suggest that a population increase in 
physical activity may help to prevent the growing prevalence of overweight and obesity 
over time (188). 
3. Interaction of diet and physical activity 
Clinical data provide strong evidence that physical activity attenuates the effects of 
HF diets on positive energy balance. Overall, energy balance was determined not by diet 
or physical activity alone, but by the interaction between the two (16). Figure 1 shows the 
hypothetical risk of developing obesity in individuals consuming a high-energy density 
diet, for example, a typical W estem diet. These individuals can maintain a relatively low 









Figure 1. Hypothetical risk of obesity in individuals consuming a diet high in energy density. 
This risk can be modified by physical activity and by conscious limitation of total energy intake 
(dietary restraint). As the energy density of the diet decreases, the risk of obesity (the height of all 
of the bars) would be expected to decline (From Hill 1998, Science 280, 1371)  
by a combination of moderate activity with some dietary restraint. For sedentary 
individuals, a high level of dietary restraint or consumption of a diet low in energy 
density is required to avoid positive energy balance. 
III. Role of Intracellular Ca2+ ([Ca2+] 1) in Obesity 
A. Unifying 'ionic hypothesis' 
Obesity is closely related to other metabolic disorders, including insulin resistance/ 
hyperinsulinemia, hypertension and dyslipidemia, which are integrated into a metabolic 
syndrome referred to as 'Syndrome X' (189), or the 'deadly quartet' (obesity, 
hypertriglyceridemia, hypertension and insulin resistance/hyperinsulinemia) (190). 
Considerable evidence suggests that these conditions are all characterized by an 
underlying impairment in [Ca2+]i. Sustained elevations of [Ca2+]i have been observed in 
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vascular smooth muscle cells, platelets, and erythrocytes in patients with hypertension 
(191-195), skeletal muscle cells and adipocytes in patients with insulin resistance (196-
199), and cardiomyocytes in patients with left ventricular hypertrophy (195). 
Correspondingly, Resnick proposed a unifying 'ionic hypothesis', in which a common 
cell lesion underlying these disorders in different tissues was characterized, in part, by 
elevations in steady-state [Ca2+]i levels (195). Consistent with this hypothesis, 
antagonism of Ca2+ influx results in clinical improvements in blood pressure, insulin 
resistance, platelet aggregation, and left ventricular hypertrophy (195). Draznin et al. first 
reported that obese patients exhibited an elevation in basal adipocyte [Ca2+]i (196). 
Further, studies of the mechanisms of agouti-induced obesity indicate that obesity may 
also be partly a manifestation of a 'lesion' in [Ca2+]i regulation (63-70). 
B. Agouti regulation of adipocyte [Ca2+Ji and lipid metabolism 
Agouti was the first obesity gene cloned (51). In addition to the aforementioned 
central effects of agouti via MC4-R antagonism, peripheral actions of agouti signaling in 
adipocytes and pancreatic J3-cells may also contribute to agouti-induced obesity via 
modulation of [Ca2+]i (57). 
The carboxyl terminus of agouti protein not only retains full functional activity 
relative to the intact protein in an in vitro assay system (200) but also exhibits a striking 
structural homology in both number and spacing of cystein residues to the ro-conotoxins 
and the plectoxins, two toxins produced by the cone snail Conus geographus and the 
hunting spider Plecteurys tristis, respectively, that primarily target Ca2+ channels (63). 
This homology between the carboxyl terminus of agouti and ro-conotoxins and the 
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plectoxins suggests that agouti may act directly upon Ca2+ channels and thereby modify 
channel activity. 
Consistent with this, the obese AY la yellow mice exhibit increases in both Ca2+ influx 
and steady-state [Ca2+]i in several tissues (64). This increase in [Ca2+]i was closely 
correlated with both the degree of ectopic agouti expression and body weight, suggesting 
the possibility of a causal mechanism between [Ca2+]i and obesity in these animals. 
Further, recombinant murine and human agouti proteins caused dose-dependent increases 
in Ca2+ influx and steady-state [Ca2+]i in a variety of cell types, including both murine 
and human adipocytes (65). This action of agouti in increasing [Ca2+]i was inhibited by 
Ca2+ channel antagonism ( 65) and mimicked by Ca2+ channel agonists ( 69). 
Fatty acid synthase (FAS) is a multifunctional enzyme that is highly regulated by 
nutrients and hormones and is rate-limiting in de novo lipogenesis (190). It has been 
reported that FAS expression and activity are markedly increased in AY/a mice relative to 
control mice ( 66), and that nanomolar concentrations of recombinant agouti protein 
stimulate ""two-fold increases in FAS gene expression and activity and triglyceride 
accumulation in 3T3-Ll adipocytes, as well as in human adipocytes, similar to the 
maximal increases stimulated by insulin ( 66). This agouti modulation of FAS and 
lipogenesis is dependent upon Ca2+ influx, as it can be mimicked in the absence of agouti 
via Ca2+-channel activation and inhibited by Ca2+-channel antagonism (66-68). 
Indeed, Ca2+ -channel blockade has been shown to reduce body weight and fat pad 
mass effectively in several animal models. Ca2+ - channel antagonists, such as nifedipine, 
verapamil and felodipine, caused decreases in body weight and fat pad mass in obese 
SHHF/Mcc-facp rats (201, 202). Similarly, treatment of transgenic mice ubiquitously 
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expressing agouti under the control of the P-actin promoter with a Ca2+ - channel 
antagonist (nifedipine) for 4 weeks resulted in significant decreases in adipocyte 
lipogenesis and an 18% reduction in fat pad mass (203). 
The human homologue of agouti, agouti signaling protein (ASIP), is expressed 
primarily in adipose tissue ( 56). Previous studies from our laboratory demonstrated that 
ASIP stimulated lipogenesis in both human and murine adipocytes via a Ca2+ -dependent 
mechanism (66-68, 204). Moreover, ASIP expression was highly correlated with in vivo 
FAS expression and activity in human adipose tissue (204). Thus, ASIP, a physiological 
Ca2+ agonist, may play a role in human obesity, mimicking overexpression of agouti in 
obese yellow mouse. Interestingly, a recent study involving 8 obese men and 14 obese 
women showed that ASIP is not only associated with obesity but also gender specific 
(205). BMI and ASIP gene expression were negatively correlated in men, whereas a 
positive relationship was observed in women. Hip circumference was significantly higher 
in women than men. Thus, the sexual dimorphism in the relationship between ASIP and 
BMI may contribute to the recognized differences in parameters such as hip fat mass 
distribution between men and women. 
In addition to activating lipogenesis, increasing [Ca2+]i may also contribute to 
increased triglyceride stores by inhibiting lipolysis. Adipose tissue from obese AY/a 
yellow mice exhibited a 50% reduced basal lipolytic rate compared to wild-type 
littermates (72, 206, 207). The response of this obese adipose tissue to epinephrine (72) 
and p agonists (206, 207) was also lower than normal. Increasing Ca2+ influx with either 
arginine vasopressin or epidermal growth factor was reported to inhibit lipolysis in rat 
adipocytes in a Ca2+ -dose responsive fashion (208). Further, agouti protein similarly 
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inhibits both basal and agonist-stimulated lipolysis in human adipocytes via a Ca2+ -
dependent mechanism. This inhibition can also be mimicked by Ca2+ channel agonists 
and reversed by Ca2+ channel antagonists (69). The anti-lipolytic effect of [Ca2+]i is due 
to a direct activation of adipocyte phosphodiesterase (PDE) 3B, resulting in a decrease in 
cAMP and, consequently, reduced ability of agonists to stimulate phosphorylation and 
activation of hormone-sensitive lipase (HSL) (209). Thus, agouti regulation of adipocyte 
[Ca2+]i appears to promote triglyceride storage in human adipocytes by coordinately 
stimulating lipogenesis and inhibiting lipolysis. 
Finally, it is noteworthy that an agouti interaction with insulin is required for the full 
expression of agouti-induced obesity since aP2-agouti transgenic mice become obese if 
they are also hyperinsulinemic as a result of either exogenous insulin or a high sucrose 
diet, while hyperinsulinemia was without effect on body weight in non-transgenic 
littermate controls (73). Further, hyperplasia of J3-cells precedes the development of 
obesity in AY/a yellow mice (210), suggesting that hyperinsulinemia may be a direct 
effect of agouti acting on the pancreas. Since increased [Ca2+]i is a primary signal for 
insulin release and agouti increases [ Ca2+]i in several cell types, agouti may stimulate 
pancreatic Ca2+ influx and insulin release as well. Indeed, agouti is expressed and causes 
a 5-fold increase in Ca2+ influx and a 2.2-fold increase in insulin release in human 
pancreatic islets, as well as in J3-cell lines (70), suggesting a potential role for agouti in 
the development ofhyperinsulinemia in humans and in obese AY/a yellow mice. This 
hyperinsulinemia may act in an additive or synergistic manner with agouti-stimulated 
adipocyte Ca2+ influx to increase adipocyte triglyceride accumulation (75). In fact, agouti 
protein and insulin exert independent, additive effects on FAS transcription, with a 6-fold 
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increase resulting from their combination versus a 2-3-fold increase from each 
independently (74). FAS responses to agouti are mediated by a distinct agouti/ Ca2+ 
response sequence in the FAS promoter. This sequence maps to the -435 to -415  region 
of the FAS promoter and is upstream of the insulin response element, which maps to -67 
to -52, consistent with the observed additive effects of agouti and insulin on FAS gene 
transcription (74). Based on these findings, since humans exhibit a similar pattern of 
adipocyte agouti expression (56), similar agouti/insulin/ Ca2+ interactions may result in 
excessive adipocyte triglyceride storage. 
Taken together, these data indicate that regulation of adipocyte [Ca2+]i, possibly 
coupled with pancreatic [ Ca2+]i and insulin release, may be an important target for the 
development of therapeutic strategies for the prevention and treatment of obesity, as 
shown in Figure 2 (57). 
C. la, 25-(0H)2-D1 modulation of adipocyte [Ca2+Ji and energy metabolism 
Several lines of evidence have suggested a role for la, 25-(0H)2-D3, the biologically 
active form of the vitamin D, in obesity. Circulating la, 25-(0H)2-D3 levels are elevated 
in obese individuals (2 1 1 , 2 12). Vitamin D receptor (VDR) gene polymorphisms are 
associated with susceptibility to obesity in patients with early onset type II diabetes (2 13). 
Two single nucleotide polymorphisms (SNPs) in nuclear VDR (nVDR) gene intron 8 and 
exon 9 account for a 9-kg body weight difference, or 4 kg/m2 . Moreover, human body 
weight and BMI have been shown to be associated with a Bsml restriction site 







Figure 2. Agouti modulation of adiposity. Agouti stimulates Ca2+ influx in pancreatic J3-cells, 
resulting in increased insulin release. Agouti stimulates Ca2+ influx in adipocytes, resulting in 
increased fatty acid synthase (FAS) transcription and activity and inhibition of lipolysis. The 
agouti-induced insulinemia augments the effects of agouti on adipocytes by independently 
increasing FAS transcription and inhibiting lipolysis. (From Zemel 200 1 ,  CRC press) 
contribute to the development of obesity, as la, 25-(0H)2-D3 stimulates insulin secretion 
(215-217), and VDR gene polymorphism affects insulin secretion and susceptibility to 
diabetes (218, 219). In vitro studies show that la, 25-(0H)2-D3 modulates adipocytes 
differentiation in several cell models (220-223). Moreover, la, 25-(0H)2-D3 promotes 
the expression and secretion of lipoprotein lipase in cultured adipocytes (224), indicating 
that 1 a, 25-(0H)2-D3 may enhance adipocyte lipid accumulation by increasing fatty acid 
uptake. 
It has been previously shown that 1 a, 25-(0H)i-D3 stimulates Ca2+ influx in a variety 
of cells (217, 225-228), including vascular smooth muscle cells (227) and pancreatic J3-
cells (217) and to play a role in the development of hypertension and hyperinsulinemia, 
respectively. This effect is rapid and mediated by a putative membrane vitamin D 
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receptor (m VDR) rather than via the classical n VDR (226, 228). Baran et al. found the 
plasma membrane-bound protein annexin II to exhibit specific and saturable binding for 
la, 25-(0H)2-D3, and suggested that it may regulate the rapid effect of la, 25-(0H)2-D3 
on [Ca2+]i (229). 
Recent data from our laboratory demonstrated that la, 25-(0H)2-D3 also stimulates 
Ca2+ influx in primary cultures of human adipocytes (230, 231 ), resulting in significant, 
sustained dose-responsive increases in steady-state [Ca2+]i. Further, la, 25-(0H)2-D3 
caused 50%-100% increases in adipocyte FAS activity and mRNA expression, and an 
80% inhibition of lipolysis stimulated by isoproterenol, a �-AR agonist (231 ). These 
effects were mimicked by la, 25-(0H)i-lumisteroh, a specific agonist for mVDR, and 
completely blocked by 1 �' 25-(0H)2-D3, a specific antagonist for m VDR (231 ). Thus, 
1 a., 25-(0H)2-D3 modulates adipocyte Ca2+ signaling via nongenomic action and, 
consequently, exerts a coordinated activation of FAS and inhibition of lipolysis, resulting 
in an expansion of adipocyte triglyceride stores, similar to the action of agouti on 
adipocytes. More recently, we reported that 1 a, 25-(0H)2-D3 exerted an inhibitory effect 
on adipocyte UCP2 mRNA and protein levels (232), which may result in decreased 
thermogenesis and subsequently increased metabolic efficiency. This effect is 
independently of la, 25-(0H)i-D3-mediated Ca2+ influx and the mVDR, and is instead 
mediated via the n VDR, indicating a novel role of n VDR in regulating adipocyte energy 
metabolism. 
In summary, la, 25-(0H)2-D3-mediated both nongenomic action via Ca2+ signal 
transduction in regulating adipocyte lipid metabolism and genomic action of inhibiting 
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UCP2 expression via n VDR in regulating metabolic efficiency may represent a suitable 
target for the development of pharmacological and/or nutritional intervention in obesity. 
IV. Role of Dietary Calcium in Modulation of Adiposity 
It is now well recognized that dietary calcium plays important roles in the 
maintenance of bone mass, and in the regulation of hypertension, a major risk factor for 
cardiovascular disease (233). McCarron, in his evaluation of the relationship between 
blood pressure and nutrient intake in the U. S population in 1984, first predicted an 
inverse relationship between dietary calcium and systolic blood pressure (234). Since 
then, numerous well-controlled studies, especially the DASH (Dietary Approaches to 
Stop Hypertension) randomized clinical trial, demonstrated that dietary calcium reduces 
blood pressure (235-237). Notably, the heterogeneity in the blood pressure response to 
increasing calcium intake was significantly less when dairy sources of calcium as 
compared to calcium supplements were used in the studies (238). This protective effect of 
dietary calcium can be explained in large part via suppression of calcitrophic hormones 
[la.,25-(0H)2-D3 and/or parathyroid hormone (PTH)] by dietary calcium, thereby 
normalizing [ Ca2+]i in vascular smooth muscle cells since elevated [ Ca2+]i increased 
vascular smooth muscle tone, peripheral vascular resistance and blood pressure (239). 
McCarron also noted a significant inverse relationship between calcium intake and body 
weight in that same study in 1984 (234). Since then, accumulating animal and human 
studies now suggest that dietary calcium not only reduces the risk of hypertension and 
cardiovascular disease, but may play an important role in the prevention and treatment of 
obesity as well, probably via modulating [Ca2+]i. 
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.A. . .A.nitn.al studies 
Metz et al. (240) and Bursey et al. (241) previously reported that increased dietary 
calciUtn. reduced body weight and body fat cotn.position in spontaneously hypertensive 
rats (Wistar-Kyoto rats and lean and obese Zucker rats). However, they were unable to 
detn.onstrate the tn.echanistn. involved in this adiposity tn.odulation . .A.lthough sotn.e 
investigators have attributed the effect of dietary calciUtn. on lipid tn.etabolistn. to 
inhibition of dietary fat absorption or fecal fat loss, significant fecal energy loss does not 
result frotn. tn.oderate increases in dietary calciUtn. (242-244). 
Multiple studies have shown that increasing dietary calciUtn. suppressed 1 a, 25-
(0H)2-D3 levels (195, 245). Moreover, la, 25-(0H)2-D3 stitn.ulates Ca2+ influx in 
adipocytes, thereby protn.otes triglyceride accUtn.ulation by coordinate stitn.ulation of 
lipogenesis and inhibition of lipolysis (230, 231 ). Consequently, suppression of 1 a, 25-
(0H)2-D3 with high calciUtn. diets would be anticipated to reduce adipocyte [Ca2ii , 
stitn.ulate lipolysis, inhibit lipogenesis, thereby exerting an anti-obesity effect. 
This concept was first confirmed in aP2-agouti transgenic tn.ice (transgenic tn.ice 
expressing agouti in adipose tissue under the control of the aP2 protn.oter, sitn.ilar to the 
hUtn.an pattern of expression) using non-fat dry tn.ilk (230). Mice were placed on a low­
calciUtn. (0.4%)/high-fat/high-sucrose diet either unsuppletn.ented or with 25 or 50% of 
the protein replaced by non-fat dry tn.ilk or suppletn.ented to 1.2% Ca with calciutn. 
carbonate for 6 weeks . .A.t the end of the study, tn.ice on low calciUtn. (0.4%) diet 
exhibited tn.arked increases in adipocyte lipogenesis, inhibited lipolysis, and accelerated 
increases in body weight and adipose tissue tn.ass. However, all three high calciUtn. 
(1.2%) diets reduced FAS expression and activity by 51 % and stitn.ulated lipolysis 3 to 5-
50 
fold, resulting in 26 to 39% reductions in body weight and adipose tissue mass, 
respectively. The magnitude of these effects depended upon the source of dietary 
calcium, with dairy sources of calcium exerting significantly greater effects than calcium 
carbonate. Thus, increasing dietary calcium modulates adipocyte lipid metabolism by 
coordinatedly down-regulating lipogenesis and up-regulating lipolysis, and attenuates 
diet-induced obesity risk. 
A follow-up study was conducted to determine whether increasing dietary calcium 
would accelerate fat loss secondary to caloric restriction following dietary induction of 
obesity (246). Administration of the same low-calcium(0.4%)/high-fat/high-sucrose diet 
to aP2-agouti transgenic mice for 6 weeks resulted in a ,..,, 100% increase in adipocyte 
[Ca2+]i and a corresponding weight gain of 29% and a 2-fold increase in total fat pad 
mass, demonstrating that elevation of adipocyte [Ca2+]i is associated with increased 
adiposity in aP2-agouti transgenic mice. The animals were then placed on energy 
restriction (70% of an ad libitum fed control group) for an additional 6 weeks. Energy 
restriction on the low calcium diet (0.4%) failed to reduce [Ca2+]i and only reduced body 
weight and fat pad mass by 11 % and 8%, respectively. In contrast, energy restriction in 
conjunction with high calcium (1.2%) diets normalized [Ca2+]i and resulted in 19 to 29% 
reductions in body weight and 42 to 69% decreases in fat pad mass depending on calcium 
sources ( elemental vs. dairy). Interestingly, the animals on the low calcium diets were 
unable to increase adipocyte lipolysis or suppress lipogenesis despite being on an energy­
restricted regimen. In contrast, the high calcium diets caused marked reductions in FAS 
expression and activity (35 to 81 %), 2 to 3-fold increases in lipolysis during energy 
restriction. In addition, ad lib feeding of the basal low-calcium diet caused sustained 
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hyperinsulinemia in the aP2-agouti transgenic mice. Energy restriction per se reduced the 
plasma insulin levels, but increasing dietary calcium did not further reduce insulin levels 
but nonetheless exerted potent effects on body weight and fat pad mass reduction. This 
indicates that the effects of dietary calcium on attenuating weight gain and accelerating 
weight loss are not due to insulin suppression and instead are likely to result from the 
observed suppression of adipocyte [Ca2+]i by suppressing la, 25-(0H)2-D3 and 
subsequent modulation of adipocyte lipid metabolism. Notably, dairy calcium (non-fat 
dry milk) exerts approximately twice the effect of the calcium supplement on both 
adipocyte lipid metabolism and on body fat and body weight despite that all three high 
calcium diets exerted comparable effects in lowering [Ca2+]i. This finding suggests that 
other components of dairy may act via a Ca2+ -independent system to further reduce 
adiposity. 
In this study, it was also found that mice fed high calcium diets exhibited higher core 
temperature (0.48 to 0.67°C) and increased expression of white adipose tissue UCP2. 
UCP2 has been shown to stimulate mitochondrial proton leak and therefore play a 
potential role in thermo genesis, metabolic efficiency and obesity (102, 103). Core 
temperature is an indirect metabolic index associated with thermogenesis. In fact, an 
increased core temperature was observed in another study in transgenic mice ubiquitously 
expressing agouti under the control of the �-actin promoter after mice were treated with 
Ca2+ channel antagonist nifedipine (203). The contribution of thermogenesis to anti­
obesity action of Ca2+ channel blockade has been addressed in previous studies (24 7, 
248). However, this mechanism remains controversial in that some investigators have 
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attributed the thermogenic effect of Ca2+ channel blockade to the increased function of 
BAT. This study of dietary calcium modulation of adiposity suggests that up-regulation 
of UCP2 expression may be responsible for the increased thermo genesis. This concept 
has been confirmed by our recent study demonstrating that la, 25-(0H)i-D3 exerted an 
inhibitory effect on adipocyte UCP2 mRNA and protein levels via the n VDR, 
independent of its effects on Ca2+ influx via the mVDR (232). Thus, suppression of la, 
25-(0H)i-D3 with high calcium diets and consequent up-regulation of UCP2 via a 
genomic action may contribute to our observations of increased thermo genesis in mice 
fed with high calcium diets. This effect, coupled with decreased lipogenesis and 
increased lipolysis secondary to decreased [Ca2+]i mediated by nongenomic action may 
contribute to an anti-obesity effect of dietary calcium as shown in Figure 3 (233). 
Ca2+ 





Figure 3. Mechanisms of the anti-obesity effect of dietary calcium (From Zemel 2002, J. Am. 
Coll. Nutr. 2 1 ,  146S) 
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This concept of dietary calcium modulation of adiposity was further extended in aP2 
agouti-transgenic mice by using a calcium-fortified breakfast cereal as a calcium source 
to increase dietary calcium from 0.4% to 1.2% (249). The effects of the high calcium 
cereal were similar to those described above for calcium carbonate, producing significant 
attenuation of diet-induced obesity and acceleration of weight/fat loss during caloric 
restriction. Interestingly, the addition of a small amount of non-fat dry milk, sufficient to 
increase dietary calcium from 1.2% to 1.3% (with dietary macronutrients held constant) 
doubled the rate of fat loss. Thus, dairy sources of calcium exert a greater anti-obesity 
effect than calcium carbonate. Although the additional factor(s) in dairy responsible for 
this effect have not yet been identified, milk is recognized as a rich source of bioactive 
compounds (250), which may act independently or synergistically with the calcium to 
attenuate lipogenesis, accelerate lipolysis and/or affect nutrient partitioning between 
adipose tissue and skeletal muscle. Notably, milk proteins have been reported to contain 
significant angiotensin-1 converting enzyme (ACE) inhibitory activity (251, 252). The 
ACE hydrolyses largely inactive decapeptide angiotensin I to octapeptide angiotensin Il 
(All), which increases blood pressure (252). In addition to its synthesis in the classical 
rennin angiotensin system, the hypertensive hormone All is secreted from adipose tissue 
as well (253, 254). Moreover, All exerts an insulin-like effect in adipocytes and acts as a 
lipogenic hormone to increase FAS enzyme activity and mRNA content, subsequently 
increasing fatty acid and triglyceride synthesis (255). Indeed, inhibition of the rennin­
angiotensin system mildly attenuates obesity in rodents, and limited clinical observations 
support this concept in hypertensive patients treated with ACE inhibitors (256). 
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Collectively, the primary effect of dietary calcium appears to be inhibition of 1 a,25-
( 0H)2-D3 effects on energy storage and utilization. Adipocyte Ca2+ signaling is an 
attractive target for the development of obesity interventions (57, 233, 239). 
B. Human studies 
Since McCarron first noted a significant inverse relationship between calcium intake 
and body weight in his evaluation of the relationship between blood pressure and nutrient 
intake in the U. S population in 1984 (234), several lines of evidence from human studies 
have supported this relationship although the mechanism was not explored at that time. 
Data from the Nationwide Food Consumption Survey (1987-88) demonstrated that 
individuals with the lowest calcium intakes tended to have the highest body weights. 
Moreover, African-Americans consume the lowest level of calcium and exhibit the 
greatest prevalence of obesity (257). During the course of a clinical trial investigating the 
antihypertensive effect of calcium in obese African-Americans, it was noted that 12  
months of yogurt supplementation, sufficient to raise daily calcium intake from 
approximately 400 to 1000 mg/day, resulted in a 4.9 kg reduction in body fat in obese 
African-Americans without an accompanying reduction in caloric intake (230). 
A randomized clinical trial demonstrated a markedly greater weight loss (7.0 vs. 1 .7 
kg) in patients maintained on a milk-based diet for 16  wk, compared with those 
maintained on conventional hypocaloric diet at the same level of energy intake (258). 
Although this difference was attributed to the novelty of the milk-based diet possibly 
contributing to a greater level of compliance, our data suggest that this effect may also be 
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attributed to suppression of la.,25-(0H)2-D3 and adipocyte [Ca2+]i by dairy calcium, with 
a consequent reduction in the efficiency of energy utilization. 
Recently, accumulating human studies strongly support the anti-obesity effect of 
dietary calcium. In a two-year prospective study of 54 normal weight young women aged 
18  to 3 1  years participating in an exercise intervention (259), subjects with high calcium 
intake, corrected by total energy intake, gained less body weight and body fat than those 
with low calcium intake. Moreover, increased total calcium and dairy calcium intakes 
predicted fat mass reductions independently of caloric intake for women at lower energy 
intakes (below the mean of 1 ,876 kcal/d). In Phase 2 of the Quebec Family Study, adults 
between 20 and 65 years of age (235  men and 235 women) were divided into three 
groups according to their daily calcium intake as follows: group A<600mg, group B 
between 600 and 1000 mg and group C> 1000mg. It was found that a low daily calcium 
intake is associated with an increase in body fat, particularly in women (260). 
Davis et al. (261) have conducted a series of calcium intervention studies designed 
with the bone mass the original outcome variable, and have recently re-evaluated these 
data with body weight and body fat the outcome variable. The re-analysis involved 780 
women who participated in five clinical trials (i.e., four observational and one double­
blind, placebo-controlled randomized trial). Analysis reveals a consistent negative 
associations between calcium intake and body weight for all age groups (3rd, 5th and 8th 
decades of life), and an odds ratio for being overweight of 2.25 for young women in the 
lower half versus the upper half of calcium intake. Data from the randomized controlled 
trial demonstrated a calcium treatment effect of 0.325 kg weight loss per year over four 
years with no intentional change in caloric intake; overall, the relationships derived from 
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this re-analysis indicate that a calcium intake increase of 1000 mg/day is associated with 
an 8 kg reduction in body weight. 
A similar beneficial effect of dietary calcium on body fat mass accumulation has been 
demonstrated in growing children as well. In one short-term study (262), 50 healthy non­
obese children with low calcium intakes (<800mg daily) aged 2.5 to 8.8 years were 
studied for 6 months. The children were randomly divided into a dairy or control group. 
The dairy group was supplemented to 1200 mg calcium or 4 servings of dairy foods 
daily. Control children ingested their usual diet with calcium intake less than 800 mg 
daily. At the end of 6 months, children from the dairy group gained less body fat than 
those from the control group. Similarly, in another five-year longitudinal study of 
preschool children (263), higher mean longitudinal calcium intakes and more 
servings/day of dairy products were associated with lower body fat. 
To extend those findings of dietary calcium modulation of adiposity in aP2-agouti 
transgenic mice to humans, we recently conducted a clinical trial involving 32 obese 
adults (264). They were maintained for 24 weeks on balanced 500 kcal/day deficit diets 
and randomized to control group (400-500mg Ca/day), high calcium group (control diet 
supplemented with 800 mg Ca/day), or high dairy group (3-4 servings of low-fat dairy 
products/day, total Ca intake of 1200-1300 mg/day) . At the end of the study period, 
patients from the control group lost only 6.4% of their body weight while those from the 
high calcium group and high dairy group lost 26% and 70% more, respectively. Fat loss 
followed a similar trend, with the high calcium and high dairy diets augmenting the fat 
loss found on the low calcium diet by 38% and 64%, respectively. Moreover, fat loss 
from the trunk region represented 19% of total fat loss on the low calcium diet, and high 
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calcium and high dairy diets increased this number to 50% and 66%, respectively. Thus, 
increasing dietary calcium significantly augments weight and fat loss secondary to caloric 
restriction and increases the percentage of fat lost from the trunk region. Moreover, dairy 
products exert a substantially greater effect on both fat loss and fat distribution compared 
to an equivalent amount of supplemental calcium. 
Finally, at the population level, a role for dietary calcium in modulating body 
composition was assessed via analysis of the third National Health and Nutrition 
Examination Survey (NHANES III) (230). After controlling for energy intake, age, 
race/ethnicity and activity level, the odds ratio of being in the highest quartile of percent 
body fat was reduced from 1 .0 for the first quartile of calcium intake to 0. 75, 0.40 and 
0. 16  for the second, third and fourth quartiles of calcium intake, respectively, for women; 
a similar inverse relationship was also noted in men. These data indicate that for any 
given level of energy intake and expenditure, a low calcium diet favors increased adipose 
tissue energy storage while a higher calcium diet favors increased energy utilization. 
In summary, laboratory, clinical and population data all support a significant anti­
obesity effect of dietary calcium, and dairy sources of calcium seem to exert greater 
effects than calcium supplement. Therefore, dietary calcium could be an effective 
regimen for the prevention and treatment of obesity at the population �evel. 
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PART 3 
DIETARY CALCIUM AND YOGURT ACCELERATE BODY WEIGHT AND 




We previously demonstrated a regulatory role for intracellular Ca2+ ([Ca2+] i) in 
human and murine adipocyte metabolism, with increased [Ca2+]i coordinately stimulating 
lipogenesis and inhibiting lipolysis, thereby expanding adipocyte lipid mass. More 
recently, we reported that la., 25-dihydroxyvitamin D3 [ la., 25-(0H)i-D3] stimulates 
adipocyte membrane vitamin D receptor (m VDR)-mediated Ca2+ influx, resulting in a 
similar Ca2+-mediated modulation of adipocyte lipid metabolism. la., 25-(0H)2-D3 also 
exerts an inhibitory effect on adipocyte uncoupling protein 2 (UCP2) mRNA and protein 
levels via the nuclear vitamin D receptor (nVDR), independent of its effects on Ca2+ 
influx. Furthermore, we reported that suppressing la., 25-(0H)i-D3 levels by increasing 
dietary calcium reduces adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis, 
increases thermogenesis, and consequently results in attenuation of adipocyte lipid 
accretion and weight/fat gain during over-consumption and acceleration of weight/fat loss 
during energy restriction. Notably, dairy sources of calcium exerted significantly greater 
effects than calcium in the form of calcium carbonate, although the reason for this is not 
yet clear. The present study was conducted to extend these observations by determining 
the efficacy of a fermented dairy product, yogurt, presented either unflavored or 
strawberry-flavored, compared to calcium carbonate, in accelerating weight/fat loss in 
aP2-agouti transgenic mice secondary to caloric restriction. Mice were fed a low calcium 
(0.4%)/high fat/high sucrose diet for 6 weeks, resulting in a 17% increase in body weight. 
Mice were then either maintained on the same low calcium basal diet ad lib or energy­
restricted (70% of ad lib) on this diet either unsupplemented (basal) or supplemented 
with calcium content increased to 1.2% either by replacing 34% of the protein with spray 
84 
dried plain or strawberry-flavored yogurt (with macronutrient adjustments) or by adding 
calcium carbonate for 6 weeks. Adipocyte [Ca2+]i was only slightly decreased by energy 
restriction alone but was further markedly reduced by all three high calcium diets (170±6 
nM, n=lO vs. 60±5 nM, n=30, p<0.001). The three high calcium diets caused significant 
stimulation of both basal and isoproterenol-stimulated lipolysis (78%-137%, p<0.05), 
with yogurt exerting a significantly greater effect compared to calcium carbonate 
(p<0.05). Similarly, the three high calcium diets suppressed adipocyte FAS mRNA by an 
average of 87%. Body weight, as well as individual and total fat pad weights, reflected 
these changes, with a 45% augmentation in fat loss on the two yogurt diets compared to 
that on the low calcium diet secondary to caloric restriction (p<0.001). Calcium carbonate 
supplementation produced an intermediate effect, with a lower 28% augmentation in fat 
loss compared to that on the low calcium diet secondary to caloric restriction (p<0.001). 
Furthermore, high calcium diets caused a higher core temperature and an increased white 
adipose tissue UCP2 expression, indicating increased thermogenesis and decreased 
metabolic efficiency. In conclusion, dietary calcium with calcium sources from plain 
yogurt, strawberry-flavored yogurt and calcium carbonate supplement suppress adipocyte 
[Ca2+] i and up-regulate UCP2 via suppression of lcx,25-(0H)2-D3, and thereby reduce 
energy storage, decrease metabolic efficiency and accelerate weight/fat loss during 




Since McCarron first noted a significant inverse relationship between dietary calcium 
intake and body weight in his NHANES I data analysis in 1984 (1 ), accumulating body of 
evidence strongly support the anti-obesity role of dietary calcium (2-15). However, it is 
not until recently that the mechanism underlying this dietary calcium modulation of 
adiposity is explored. 
Previous studies of the mechanism of action of the agouti gene in obesity and insulin 
resistance from our laboratory demonstrated a regulatory role for intracellular Ca2+ 
([Ca2+]i) in human and murine adipocyte lipid metabolism (16-19). Increased adipocyte 
[Ca2Ji appears to pro�ote expansion of adipocyte triglyceride stores by exerting a 
coordinated stimulation of lipogenesis and inhibition of lipolysis. Moreover, obesity in 
transgenic mice ubiquitously expressing agouti under the control of the �-actin promoter 
was markedly attenuated by 4-wk treatment of a Ca2+ - channel antagonist (nifedipine) 
(20). 
More recently, we reported that la.,25-(0H)2-D3 stimulates adipocyte Ca2+ influx via 
the m VDR, resulting in a similar Ca2+ -mediated modulation of adipocyte lipid 
metabolism (6, 21). la, 25-(0H)i-D3 also exerts an inhibitory effect on adipocyte UCP2 
mRNA and protein levels via the n VDR, independent of its effects on Ca2+ influx (22). 
Furthermore, we reported that feeding high calcium diets (non-fat dry milk) results in 
decreased adipocyte [Ca2+]i, increased thermogenesis, and attenuation of adipocyte lipid 
accretion and weight/fat gain in ad libitum fed mice and marked acceleration of 
weight/fat loss secondary to caloric restriction ( 6, 9, 10). Accordingly, we proposed that 
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suppressing la,25-(0H)i-D3 levels by increasing dietary calcium would suppress 
adipocyte [ Ca2+]i, up-regulate UCP2, and consequently inhibit lipogenesis, stimulate 
lipolysis, increase thermogenesis and decrease metabolic efficiency, thereby exerting an 
anti-obesity effect. 
Consistent with the animal observations, clinical and epidemiological observations 
support these findings (6, 8, 1 4). Epidemiologically, the effect of calcium intake on body 
fat in humans was examined in the NHANES III data set (6). After controlling for energy 
intake and energy expenditure, a strong inverse relationship was noted between calcium 
intake and body fat in both women and men. The odds ratio of being in the highest 
quartile of body fat was markedly reduced from 1 .00 for the first quartile of calcium 
intake to 0.75, 0.40, and 0. 16  for the second, third, and fourth quartiles of calcium intake, 
respectively. 
Collectively, dietary calcium may exert its anti-obesity effect for humans through the 
mechanism we proposed above, and further investigation is needed to confirm this. 
Notably, dairy sources of calcium exerted substantially greater effects in acceleration of 
weight/fat loss secondary to caloric restriction compared to the same levels of calcium in 
the form of calcium carbonate supplement ( 6, 9) although the additional component( s) of 
dairy products responsible for this difference is not yet known. Moreover, the only dairy 
product systematically tested in this manner has been non-fat dry milk (6, 9), and it is not 
clear whether other forms of dairy products will exert comparable or greater weight-loss 
effects secondary to caloric restriction. Accordingly, the present study was conducted to 
determine the efficacy of a fermented dairy product, yogurt, presented either unflavored 
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or strawberry-flavored, compared to calcium carbonate, in acceleration of weight and fat 
loss secondary to caloric restriction in aP2-agouti transgenic mice. 
III. Materials and Methods 
A. Animals and diets 
aP2-agouti transgenic mice from our breeding colony were used as an animal model 
for dietary calcium modulation of adiposity in vivo. These transgenic mice express 
normal agouti protein specifically in adipose tissue under the control of the adipose 
tissue-specific fatty acid binding protein aP2 promoter (23 ), similar to the adipocyte­
specific agouti expression in humans, and exhibit a normal pattern of leptin expression 
and activity, similar to that found in humans. These mice are useful model for diet­
induced obesity in that they are not obese on standard chow but are susceptible to diet­
induced obesity (6, 9, 24). 
This study was divided into two 6-wk stages. In the first 6-wk stage, fifty 28-wk-old 
male aP2-agouti transgenic mice weighing 37.4 ± 3.7g (mean ± SE) were placed on a 
modified AIN-93G basal diet with sub-optimal calcium (0.4%), sucrose as the sole 
carbohydrate source, and fat increased to 25% of energy with lard. In the second 6-wk 
stage, these diet-induced obese transgenic mice were randomly assigned to five groups of 
ten animals in each group. One group continued ad libitum on the same low-calcium 
(0.4%) basal diet with no further modifications, while the other four groups were 
maintained with energy intake restricted to 70% of that found in the ad lib fed group, as 
follows: ( 1 )  a basal restriction group was placed on the basal low-calcium (0.4%) diet; (2) 
a plain yogurt-fed restriction group received the basal diet with --34% protein replaced by 
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spray dried plain yogurt (Y oplait, General Mills, Inc., Minneapolis, MN) to bring the 
calcium content of the diet to 1.2%. The carbohydrate and fat content of the diet were 
adjusted to compensate for contributions from the yogurt, but no adJµstments were made 
to the micronutrient content of the diet; (3) a strawberry-flavored yogurt-fed restriction 
group, which received the basal diet with --34% of protein replaced by spray dried 
strawberry-flavored yogurt (Y oplait, General Mills, Inc., Minneapolis, MN) to increase 
dietary calcium to 1.2%, with carbohydrate and fat adjustments as described above; and 
(4) a calcium carbonate restriction group, which received the basal diet supplemented 
with calcium carbonate to increase calcium content to 1.2%. Diet was administered and 
weighed daily, and body weight was monitored twice a week. 
At the end of the second stage, all mice were sacrificed under anesthesia with a 
pentobarbital (100 mg/kg body weight)/phenytoin (12.Smg/kg) mixture (Abbott 
Laboratory, North Chicago, IL). Blood was collected via cardiac puncture for insulin 
measurement. Fat pads (abdominal, epididymal, perirenal and subscapular), 
gastrocnemius and soleus muscle were dissected and weighed immediately. The perirenal 
fat pads were utilized immediately for baseline and isoproterenol-stimulated lipolysis, as 
described below. Half of the abdominal fat pad from each animal was homogenized 
immediately and then stored at -80°C for fatty acid synthase (FAS) activity assay. The 
other half of the abdominal fat pad was frozen in liquid nitrogen immediately and stored 
at -80°C for assessment of FAS and uncoupling protein 2 (UCP2) mRNA expression. 
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B. Blood glucose, insulin and core temperature measurements 
Blood glucose was measured using the FastTake Blood Glucose Meter (Lifescan, 
Inc.) weekly with blood taken from the tail vein. Serum insulin level was measured via 
radioimmunoassay using mouse/rat insulin RIA kits (Linco Research, Inc., St. Charles, 
MO). Core temperature was used as an indirect metabolic index to determine whether 
dietary calcium regulates energy metabolism associated with increased thermogenesis, an 
important contribution to energy expenditure. Temperature was measured via a 
thermocouple (Columbus Instruments, Columbus, Ohio) weekly. The probe was inserted 
a constant distance (1.8cm) into the rectum of each mouse. After stabilization (10s), the 
temperature was recorded every 5 s for 30 s (6, 9, 20). All core temperature 
measurements were performed weekly between 8 :00 and 9:30 A.M. 
C. Mouse adipocyte intracellular Ca2+ ([Ca2+]Jmeasurement 
[Ca2+]i in isolated mouse adipocytes was measured by using a fura-2 dual wavelength 
fluorescence imaging system (Intracellular Imaging, Inc.) (9). Briefly, mouse abdominal, 
epididymal, perirenal and subscapular adipose tissues were first washed several times 
with KRB buffer containing the following components (in mmol/L): NaCl 129, NaHC03 
5, KCl 4.8, KH2P04 1.2, CaCh 2.0, MgS04 1.2, Glucose 5, HEPES 20, and bovine 
serum albumin (BSA) 0.5%. They were then minced into small pieces, and digested with 
0.8 mg/ml type I collagenase in a shaking water bath at 37°C for 1 hr. Adipocytes were 
filtered through sterile 500-µm nylon mesh, rinsed several times with KRB buffer and 
resuspended in KRB buffer. Adipocytes were then loaded with fura-2 acetoxymethyl 
ester (AM) (10 µmol /L) (Sigma, St.Louis, MO) in the same buffer and incubated in a 
90 
shaking water bath at 37°C in the dark for another 1 hr. Finally, adipocytes were rinsed 
with KRB buffer three times to remove extracellular dye, and post-incubated at room 
temperature for an additional 30 mins to ensure complete hydrolysis of cytoplasmic fura-
2 AM. A thin layer of adipocytes was plated in 35 mm dishes with glass coverslips 
(P35GC-0-14-C, MatTek Corporation, Ashland, Mass.). The dishes with dye-loaded cells 
were mounted on the stage of Nikon TMS-F fluorescence inverted microscope with a 
Cohu 4915 CCD camera. Fluorescent images were captured alternatively at excitation 
wavelength of 340 nm and 380 nm with an emission wavelength of 520nm. [Ca2+]i was 
calculated by using a ratio equation (25). 
D. Lipolysis assay 
Immediately after the dissection, perirenal adipose tissue was incubated with KRB 
buffer for 2 hrs either in the presence or absence of isoproterenol (lOOnM) in 37°C 
incubator with 5% CO2 • Glycerol released into the KRB medium was determined as an 
indicator of lipolysis by using a one-step enzymatic fluorometric method (26). Glycerol 
release data was DNA corrected using CyQuant Cell Proliferation Assay Kit (Molecular 
Probes, Eugene, OR.) 
E. Fatty acid synthase (FAS) activity assay 
FAS activity was determined spectrophotometrically in crude cytosolic extracts of 
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L 
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1 mmol/L 
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dithiothreitol (DTT), and lOOµmoVL phenylmethylsulfonyl Fluoride (PMSF) (PH7.4). 
Homogenate was centrifuged at 14,000 rpm for 1 hr at 4°C, and the infranatant was used 
for measuring oxidation rate of NADPH started by the addition of malonyl CoA (6, 9, 
18, 20). FAS activity data was DNA corrected as described in lipolysis assay. 
F. Northern blot analysis 
Northern blot analysis was conducted as previously described (6, 9). Total celluar 
RNA from mouse abdominal adipose tissue was extracted by using cesium chloride 
(CsCh) density gradient centrifugation, run in 1 % agarose gel, and transferred to nylon 
membrane (New England Nuclear, Boston, Mass.). The membrane was hybridized with 
mouse FAS or UCP-2 cDNA probes that were radiolabeled by using a random primer 
method. Unbound probe was removed by rinsing the membrane with 2XSSC/O. l %SDS 
for 30 min at room temperature and O. lXSSC/0.1 %SDS for 45 min at 55°C. Finally, 
membranes were exposed to X-ray film (New England Nuclear) at -80°C, and 
autoradiograghs were quantitated densitometrically. All membranes were stripped and re­
probed with 18S rRNA as loading control. 
G. Statistical analysis 
All data are expressed as mean ± SE. Data were analyzed for statistical significance 
via one-way analysis of variance (ANOVA), followed by separation of significantly 
different group means via the least significant difference (LSD) test using SPSS (v.10.0). 
A p value < 0.05 is considered significant. 
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IV. Results 
Administration of the basal low-calcium (0.4%)/ high-fat/ high-sucrose diet to mature 
aP2-agouti transgenic mice for six weeks resulted in a body weight gain of 1 7% 
(37.4±0.5g vs . 43 .9±0.6 g, n=50, p< 0.001 ; Fig.4), demonstrating the obesity promoting 
effect of this diet. 
Six weeks of energy restriction resulted in a body weight loss of 25%, compared to 
the ad lib basal group, which exhibited a slight (3%) further increase in body weight 
[p<0.001 ; Fig. 5 (upper panel)] . Moreover, a significantly greater weight reduction of 
3 1  % was observed in the calcium carbonate (CaC03) group [p<0.001 vs. restriction 
J,asal; Fig. 5 (upper panel)] , while the two yogurt groups exhibited a significantly greater 
40% weight loss [p<0.01 vs. restriction CaC03; Fig. 5 (upper panel)] . Similarly, energy 
restriction caused a 29% decrease in total fat pad mass [p<0.001 vs . ad lib basal; Fig .. 5 
(middle panel)], while markedly greater reductions of 49%, 72% and 76% were found 
with calcium carbonate, strawberry yogurt and plain yogurt diet, respectively [p<0.001 
vs. restriction basal; Fig. 5 (middle panel)] . The two yogurt groups exhibited significantly 
greater !eductions in fat mass than the calcium carbonate group (p<0.00 1). Interestingly, 
we also found that mice fed the two yogurt diets had significantly higher gastrocnemius 
muscle weight, adjusted for body weight, compared to the other groups [p<0.05 ; Fig.5 
(lower panel)] . 
Energy restriction caused only 17% decrease in adipocyte [Ca2Ji (1 70±6 nM vs. 
206±27 nM, p<0.05 vs. ad lib basal; Fig. 6), whereas all three high calcium diets caused 
















Figure 4. Effect of 6-week administration of basal low-calcium (0.4%) / 
high fat I high sucrose diet on body weight in aP2-agouti transgenic mice. 
Diet and animal administration was conducted as described in Materials and 
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Plain Strawberry Calcium 
Yogurt Carbonate 
Figure 5. Effect of 6-wk administration of high calcium diets (1 .2%) on body weight change 
(upper panel), fat pad mass (middle panel) and gastrocnemius muscle weight (lower panel) in 
energy-restricted (70% of ad lib) aP2-agouti transgenic mice. Diet and animal administration 
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+ p<0.00 1 vs. Restriction Basal 
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Plain Strawberry Calcium 
Yogurt Carbonate 
Figure 6. Effect of 6-wk administration of high calcium diet (1 .2%) on basal 
adipocyte [Ca2+]i in energy restricted (70% of ad lib) aP2-agouti transgenic 
mice. Diet and animal administration was conducted as -described in Materials 
and Methods . Data are expressed as mean ± SE (n=l O/group) 
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7 demonstrates that energy restriction alone did not affect adipocyte basal (upper panel) 
or isoproterenol-stimulated lipolysis (middle panel) . However, the calcium carbonate diet 
caused 78% and 8 1  % stimulation on basal and isoproterenol-stimulated lipolysis, 
respectively (p<0.05 vs. restriction basal), which were further stimulated in the two 
yogurt diet groups (p<0.05 vs. restriction CaC03). Figure 7 lower panel demonstrates that 
energy restriction caused a 59% decrease in adipocyte FAS mRNA expression (p<0.001 
vs. ad lib basal), while markedly greater reductions (84%-89%) were found with all three 
high calcium diets (p<0.05 vs. restriction basal). 
After 6-wk dietary treatment, both the plain yogurt and calcium carbonate groups 
exhibited an increase in core temperature of 0.71 and 0.76°C, respectively (p<0.05 vs. ad 
lib basal, Table 2). Figure 8 shows all three high calcium diets up-regulated white adipose 
tissue UCP2 mRNA expression by an average of 66% (p<0.01 ), while energy restriction 
alone had no significant effect. 
Six-wk feeding of the basal high fat/high sucrose/low calcium obesity-promoting diet 
exerted a diabetogenic effect with an average high blood glucose level of 1 32 ± 5 mg/dl 
and a corresponding degree of compensatory hyperinsulinemia. Energy restriction alone 
lowered plasma glucose level by 22% (139 ± 6 mg/dl vs. 109 ± 4 mg/dl, p<0.05, Table 3) 
and dramatically reduced insulin level by 74% (4.39 ± 0.84 ng/ml vs. 1 . 1 4 ± 0.3 ng/ml, 
p<0.001 ,  Table 4), and subsequently reduced plasma insulin to glucose ratio, improving 
insulin sensitivity. All the three high calcium diets did not further significantly reduced 
these parameters. 
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Plain Strawberry Calcium 
Yogurt Carbonate 
Figure 7. Effect of high calcium diets ( 1 .2%) on basal lipolysis (upper panel), isoproterenol­
stimulated lipolysis (middle panel) and FAS mRNA expression (lower panel) in energy­
restricted (70% of ad lib) aP2-agouti transgenic mice. Diet and animal administration was 
conducted as described in Materials and Methods. Data are expressed as mean ± SE 
(n=lO/group). 
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Table 2. Effect of high calcium diets (1 .2%) on core temperature change in energy­
restricted (70% of ad lib) aP2-agouti transgenic mice. Diet and animal administration 
was conducted as described in Materials and Methods. Data are expressed as 
mean ± SE (n= lO/group). ap<0.05 vs . ad lib Basal. 
Groups Before After Change 
(n= l O) (°C) (°C) (OC) 
ad lib Basal 36.7±0.30 36.41±0.22 -0.29 
Restriction 36. 1 9±0.29 36.66±0 . 1 5  +0.47 
Basal 
Plain Yogurt 35.93±0.30 36.64±0. 12  +0.7 t a 
Strawberry 36.35±0.35 36.75±0.09 +0 .40 
yogurt 
Calcium 36.33±0.36 37.09±0.09 +0.76 a 
Carbonate 
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Figure 8. Effect of 6-wk administration of high calcium diets (1 .2%) on UCP2 
mRNA expression in energy-restricted (70% of ad lib) aP2-agouti transgenic 
mice. Diet and animal administration was conducted as described in Materials 
and Methods. Data was expressed as mean ± SE {n=lO/group). 
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Table 3. Effect of 6-week energy restriction (70% of ad lib) and high calcium diets (1 .2%) 
on blood glucose level change in aP2-agouti transgenic mice. Diet and animal administration 
was conducted as described in Materials and Methods. Data are expressed as mean ± SE 
(n=lO/group). ap<0.05 vs. ad lib Basal. 
Groups Before After Change 
(n= l O) (mg/dl) (mg/dl) (mg/dl) 
ad lib Basal 129±7 1 26±5 -3 
Restriction Basal 1 39±6 1 09±4 
-
3oa 
Plain Yogurt 1 29±5 93+6 -36a 
Strawberry 1 38±6 105±8 _33a 
yogurt 
Calcium 1 25±3 99±5 -26a 
Carbonate 
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Table 4. Effects of 6-week energy restriction (70% of ad lib) and high calcium diets ( 1 .2%) 
on serum insulin level, blood glucose ievel and insulin / glucose ratio in aP2-agouti 
transgenic mice. Diet and animal administration was conducted as described in Materials 
and Methods. Data are expressed as mean ± SE (n=lO/group). 
a p<0.001 vs. ad lib Basal 
hp<0.05 vs. ad lib Basal 
Groups ad lib Restriction Plain Strawberry Calcium 
(n=lO) Basal Basal yogurt yogurt Carbonate 
Serum insulin 
4.39 ± 0.84 1 .14 ± 0.3• 0.44 ± 0.12• 1 .25 ± 0.37• 1 .13 ± 0.44• (ng/ml) 
Glucose 
126 ± 5  109 ± 4b 93 ± 6b 105 ± 8b 99 ± 5b 
(mg/di) 
i 





Data presented in this study demonstrate that high calcium diets with calcium sources 
from plain yogurt, strawberry-flavored yogurt and calcium carbonate supplement 
suppress adipocyte [Ca2+]i, up-regulate UCP2, inhibit lipogenesis, stimulate lipolysis, 
increase thermogenesis and decrease metabolic efficiency, thereby accelerating 
weight/fat loss during caloric restriction in aP2-agouti transgenic mice. Notably, yogurt 
exerted a significantly greater effect than calcium carbonate. These findings support and 
extend our previous observations using non-fat dry milk in the same mouse model (9). 
McCarron, in his evaluation of the relationship between blood pressure and nutrient 
intake in the U. S. population in 1984, first noted a significant inverse relationship 
between calcium intake and body weight (1). Since then, Metz et al. (2) and Bursey et al. 
(3) reported that increasing dietary calcium reduced body fat composition and body 
weight in spontaneously hypertensive rats (Wistar-Kyoto rats) and in both lean and 
obese Zucker rats. However, they were unable to demonstrate the mechanism involved in 
this adiposity modulation. Although some investigators have attributed the effect of 
dietary calcium on lipid metabolism to potential inhibition of dietary fat absorption or 
fecal fat loss, significant fecal energy loss does not result from moderate increases in 
dietary calcium (27-29). In a randomized controlled clinical trial of reducing diets in 
adult outpatients, those maintained on a milk-based diets for 16 wks had greater weight 
loss (7.0 vs. 1.7 kg) than patients maintained on a conventional hypocaloric diet that was 
isocaloric to the milk-based diet (5). The investigators proposed that greater compliance 
with the novel milk-based diet may have contributed to the greater weight loss. However, 
the present study, combined with our previous studies ( 6, 9), indicates that intracellular 
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Ca2+ concentration ([Ca2+]i) plays a regulatory role in this adiposity modulation exerted 
by dietary calcium. That is, high calcium diets suppress adipocytes [Ca2+]i by suppressing 
circulating calcitrophic hormone la, 25-(0H)2-D3 levels, and consequently inhibit 
lipogenesis and stimulate lipolysis, thereby exerting an anti-obesity effect. 
Several lines of evidence demonstrated that circulating la.,25-(0H)2-D3 level is 
increased in obese humans (30, 31 ). It has been previously demonstrated that increasing 
dietary calcium suppress circulating la.,25-(0H)2-D3 levels in multiple studies (32, 33). 
Moreover, la.,25-(0H)2-D3 has been shown to stimulate increases in [Ca2+]i via 
membrane vitamin D receptor (m VDR) in both vascular smooth muscle cells (34) and 
pancreatic �-cells (35) and to play a role in the development of hypertension and 
hyperinsulinemia, respectively. Importantly, we recently reported that la.,25-(0H)2-D3 
also acted on human adipocytes via mVDR to cause a sustained increase in [Ca2+]i and a 
corresponding marked inhibition of lipolysis and stimulation of lipogenesis (6, 36). Thus, 
high calcium diets would suppress circulating la.,25-(0H)2-D3 level, which would 
subsequently suppress adipocyte [Ca2+]i. Indeed, our data show that all three high calcium 
diets induced substantial decreases in adipocyte [ Ca2+]i of energy-restricted mice, 
compared to energy restriction alone. 
Draznin et al. first reported that obese patients exhibited an elevation in basal 
adipocyte [Ca2+] i (37). The physiological consequence of this elevation in adipocyte 
[Ca2+]i was addressed by our previous studies of the mechanism of action of agouti gene 
in obesity and insulin resistance. In particular, agouti protein caused dose-responsive 
increases in Ca2+ influx and steady-state [Ca2+]i in a variety of cell types, including both 
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murine and human adipocytes ( 17). Agouti protein also stimulates the expression and 
activity of fatty acid synthase (FAS), a key enzyme in de novo lipogenesis, and inhibits 
basal and agonist-stimulated lipolysis in both human and murine adipocytes ( 18, 1 9). 
Moreover, this agouti modulation of lipid metabolism is fully mimicked by Ca2+ channel 
agonists and inhibited by Ca2+ channel antagonists ( 1 8, 1 9). Indeed, Ca2+-channel 
blockade has been shown to reduce body weight and fat pad mass effectively in several 
animal models. Ca2+ - channel antagonists, such as nifedipine, verapamil and felodipine, 
caused decreases in body weight and fat pad mass in obese SHHF/Mcc-facp rats (38, 39). 
Similarly, we previously reported that treatment of transgenic mice ubiquitously 
expressing agouti under the control of the J3-actin promoter with a Ca2+ - channel 
antagonist (nifedipine) for 4 weeks resulted in significant decreases in adipocyte 
lipogenesis and an 1 8% reduction in fat pad mass (20). Therefore, increasing [Ca2+]i 
appears to promote triglyceride storage in adipocytes by coordinately stimulating 
lipogenesis and suppressing lipolysis. 
In present study, reduction of [Ca2+]i was achieved by feeding high calcium diets. Our 
data show that high calcium diets caused marked inhibition of FAS mRNA expression. 
FAS is known to be regulated primarily at transcription level by nutrients and hormones 
( 40). Moreover, both basal and isoproterenol-stimulated lipolysis were enhanced with 
high calcium diets while energy restriction alone was without effect on lipolysis. 
Correspondingly, total fat pad mass and body weight reflected these changes, with a 45% 
augmentation in fat loss on the two yogurt diets compared to that on the low calcium diet 
secondary to caloric restriction (p<0.001). Calcium carbonate supplementation produced 
an intermediate effect, with a 28% augmentation in fat loss compared to that on the low 
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calcium diet secondary to caloric restriction (p<0.001). Interestingly, energy-restricted 
mice fed on two yogurt diets had significantly higher gastrocnemics muscle weight, 
adjusted by body weight, than those maintained on ad lib basal low calcium diet. Energy 
restriction alone and the calcium carbonate supplement diet had no effect on 
gastrocnemics muscle weight. 
Taken together, these data demonstrate that dietary calcium-induced downregulation 
of adipocyte [ Ca2+]i may be associated with decreased adiposity via coordinate 
stimulation of lipolysis and inhibition of lipogenesis. Notably, yogurt exerts a greater 
effect on lipid metabolism and corresponding body weight and adipose tissue mass 
reduction compared with a comparable quantity of calcium in the form of calcium 
carbonate. The reason for this difference is not yet apparent although it is consistent with 
our previous observations (6, 9). It is interesting that all three high calcium diets exerted 
comparable effects in lowering [ Ca2+]i despite the marked differences in the effects of 
elemental versus yogurt calcium on adipose tissue mass reduction. This finding suggests 
that other components of yogurt may act via a [Ca2+]i-independent system to further 
reduce adiposity and facilitate nutrient partitioning from adipose tissue to skeletal muscle. 
Dairy proteins have been reported to contain significant angiotensin-I converting enzyme 
(ACE) inhibitory activity ( 41 ,  42), which caused decreased conversion of angiotension II 
(All) from angiotension I (AI). All not only increases blood pressure but also exerts an 
insulin-like effect in adipocytes and acts as a lipogenic hormone to increase FAS enzyme 
activity and mRNA content, subsequently increasing fatty acid and triglyceride synthesis 
(43). Indeed, inhibition of the rennin-angiotensin system mildly attenuates obesity in 
rodents, and limited clinical observations support this concept in hypertensive patients 
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treated with ACE inhibitors ( 44). However, further investigations are necessary to 
identify the additional component(s) of dairy products that contribute to the greater effect 
on energy metabolism than calcium carbonate supplement. 
Consistent with our previous study (9), high calcium diets not only modulate lipid 
metabolism involved in lipogenesis and lipolysis, but also cause a higher core 
temperature and an increased white adipose tissue UCP2 mRNA expression. In fact, we 
have also previously observed an increased core temperature in transgenic mice 
ubiquitously expressing agouti under the control of the J3-actin promoter after mice were 
treated with Ca2+ channel antagonist nifedipine (20). The contribution of thermo genesis 
to anti-obesity action of Ca2+ channel blockade has been addressed in previous studies 
( 45, 46), but the mechanism remains controversial. Some investigators have attributed the 
thermogenic effect of Ca2+ channel blockade to the increased function of brown adipose 
tissue (45, 46). The present study, combined with our previous study (9), suggest that up­
regulation of UCP2 expression may be responsible for thermogenesis since UCP2 has 
been shown to stimulate mitochondrial proton leak and therefore exhibit a potential role 
in thermogenesis, energy metabolism and obesity (47, 48). This concept was confirmed 
by our recent study demonstrating that la, 25-(0H)2-D3 exerted an inhibitory effect on 
adipocyte UCP2 mRNA and protein levels via the n VDR, independent of its effects on 
Ca2+ influx via the m VDR (22). Thus, suppression of 1 a, 25-(0H)2-D3 with high calcium 
diets and consequent up-regulation of UCP2 via genomic action may contribute to our 
observations of increased thermo genesis in mice fed with high calcium diets. This effect, 
coupled with decreased lipogenesis and increased lipolysis secondary to decreased [Ca2+]i 
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mediated by nongenomic action may contribute to an anti-obesity effect of dietary 
calcium. 
ad lib feeding of the basal low-calcium diet caused sustained hyperinsulinemia. Data 
from the present study demonstrate that energy restriction per se reduced the plasma 
insulin levels and that increasing dietary calcium did not further reduce insulin but 
nonetheless exerted potent effects on body weight loss and fat pad mass reduction. Thus, 
the effects of dietary calcium on accelerating weight/fat loss are not due to reduced 
insulin levels and instead are likely to result from the observed suppression of adipocyte 
[Ca2+]i and modulation of adipocyte lipid metabolism. 
Recently, accumulating human studies strongly support the anti-obesity effect of 
dietary calcium (7, 8, 11-15). Davis et al. (8) have conducted a series of calcium 
intervention studies in women designed with the bone mass the original outcome 
variable, and have recently re-evaluated these data with body weight and body fat the 
outcome variable. The re-analysis reveals a consistent negative association between 
calcium intake and body weight for all age groups (3rd, 5th and 8th decades of life), and 
an odds ratio for being oveiweight of 2.25 for young women in the lower half versus the 
upper half of calcium intake. Data from the randomized controlled trial demonstrated a 
calcium treatment effect of 0.325 kg weight loss per year over four years with no 
intentional change in caloric intake; overall, the relationships derived from this re­
analysis indicate that a calcium intake increase of 1000 mg/day is associated with an 8 kg 
reduction in body weight. A similar beneficial effect of dietary calcium on body fat mass 
reduction has been demonstrated in growing children as well. Carruth and Skinner 
reported that higher longitudinal intakes of calcium and servings of dairy products were 
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associated with lower body fat in preschool children (12). Finally, our recent clinical trial 
on obese subjects demonstrates that increasing dietary calcium significantly augments 
weight and fat loss secondary to caloric restriction and increases the percentage of fat lost 
from the trunk region. Moreover, dairy products exert a substantially greater effect on 
both fat loss and fat distribution compared to an equivalent amount of supplemental 
calcium (14). 
In summary, high calcium diets with calcium sources from plain yogurt, strawberry­
flavored yogurt and calcium carbonate supplement exert potent effects in enhancing 
reduction of body weight and fat pad mass in energy-restricted aP2-agouti transgenic 
mice by suppressing adipocyte [Ca2+]i, up-regulating UCP2 in adipocytes, and 
consequently inhibiting lipogenesis, stimulating lipolysis, increasing thermogenesis and 
decreasing metabolic efficiency. Notably, yogurt exerted a significantly greater effect 
than calcium in the form of calcium carbonate. Thus, fermented dairy products may be 
useful for further development of effective dietary intervention in obesity. 
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The objective of this thesis research was to extend our previous observations of anti­
obesity role of dietary calcium by determining the efficacy of a fermented dairy product, 
yogurt, presented either unflavored or strawberry-flavored, compared to calcium · 
carbonate, in accelerating weight and fat loss secondary to caloric restriction in aP2-
agouti transgenic mice. 
This thesis has demonstrated that high calcium diets with calcium sources from plain 
yogurt, strawberry-flavored yogurt and calcium carbonate supplement suppress adipocyte 
[Ca2+]i and up-regulate UCP2 via suppression of la,25-(0H)2-D3, and thereby reduce 
energy storage via coordinately stimulating lipolysis and inhibiting lipogenesis, decrease 
metabolic efficiency via increasing thermogenesis, and accelerate body weight/fat loss 
during energy restriction, with significantly greater effects exerted by yogurt than by 
supplemental calcium. These findings extend our previous observations using non-fat dry 
milk in the same mouse model and further confirm the mechanisms underlying this 
dietary calcium modulation of adiposity we proposed earlier. At the same time, 
accumulating human studies also strongly support an anti-obesity role for dietary 
calcium. In conclusion, dietary calcium, especially dairy calcium, may be effective 
dietary regimen for the treatment of obesity. 
Further investigations are necessary to identify the additional component( s) of dairy 
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